CURRICULUM VITAE

DATE: September 30, 2022

NAME: Salma K. Jabbour, M.D.

PRESENT TITLE: Professor, Vice Chair of Clinical Research and Faculty Development, Department of Radiation Oncology; Clinical Chief of the Radiation Oncology Clinic at RWJBH-New Brunswick/CINJ

OFFICE ADDRESS: 195 Little Albany St. New Brunswick, NJ 08903

TELEPHONE NUMBER/E-MAIL ADDRESS: 732-757-9840/jabbousk@cinj.rutgers.edu

CITIZENSHIP: US Citizen, Born in Silver Spring, MD, USA

EDUCATION:

A. Undergraduate Graduate and Professional
University of Virginia
Charlottesville, VA
Echols Scholar
B.A. in Biology, with Distinction
May 1996

B. Graduate and Professional
University of Maryland School of Medicine
Baltimore, MD
Medical Doctor, Cum Laude
May 2001

POSTGRADUATE TRAINING:

A. Internship and Residencies

University of Maryland Medical Center
Department of Medicine
Internship
6/2001 – 6/2002

Johns Hopkins University School of Medicine
Department of Radiology Oncology and Molecular Radiation Sciences
Assistant Resident
7/2002 – 6/2005

Johns Hopkins University School of Medicine
Department of Radiation Oncology and Molecular Radiation Sciences
Resident (Chief Resident)
7/2005-6/2006

Rutgers Leadership Academy
Rutgers University
9/2017-6/2019

B. Research Fellowships N/A

C. Postdoctoral Appointments N/A

MILITARY: N/A

ACADEMIC APPOINTMENTS:

Rutgers Cancer Institute of New Jersey
Radiation Oncology Disease Specific Group Leader
1/1/2022-present

Clinical Chief of the Radiation Oncology Clinic at RWJBH-New Brunswick/CINJ
Rutgers Barnabas Health/Rutgers Cancer Institute of New Jersey
9/1/2020-9/30/2022

Department of Radiation Oncology
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
Vice Chair, Clinical Research and Faculty Development
2/1/2018-present

Department of Radiation Oncology
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
Professor
7/1/2017-present

Rutgers Cancer Institute of New Jersey
Human Research Oversight Committee (DSMC)
Co-Chair
1/2019-present

Rutgers Cancer Institute of New Jersey
Gastrointestinal Tumor Study Group
Co-Leader
3/2017-present

Department of Radiation Oncology
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
Director of Education
2/2016-2/2018

Department of Radiation Oncology
Rutgers Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
Associate Professor
3/2013-6/30/2017

Department of Radiation Oncology/CINJ
University of Medicine and Dentistry of New Jersey
Assistant Professor
8/2006 – 3/2013

Department of Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins Hospital

Chief Resident
7/2005 – 6/2006
(7/2006-8/2006 - Studying for board examinations and moving to a new state)

HOSPITAL APPOINTMENTS:

Department of Radiation Oncology
Robert Wood Johnson University Hospital
Radiation Oncologist
9/2006 - Present

Department of Radiation Oncology
RWJUH-Hamilton Cancer Center
Radiation Oncologist
11/2006 - Present

Department of Radiation Oncology
RWJMS – Newark
Radiation Oncologist
7/2010 – 6/2011

Department of Radiation Oncology
Raritan Bay Medical Center
Radiation Oncologist
6/2007 – 6/2010

OTHER EMPLOYMENT OR MAJOR VISITNG APPOINTMENTS: N/A

PRIVATE PRACTICE: N/A

LICENSURE: Medical Doctor/25MA08085900 (expiration 6/30/2023)

DRUG LICENSURE:

CDS: D0823500 (expiration 12/31/2021)
DEA: FJ0027626 (expiration 12/31/2021)

CERTIFICATION: Radiation Oncology - 06/2007 - 07/2027

LEADERSHIP ASSIGNMENTS IN PROFESSIONAL SOCIETIES:

Caris LifeSciences Precision Oncology Alliance
Radiation Oncology Chair
Radiation Working Group
January 2022-present

American Board of Radiology
Continuing Certification Committee
January 2022- present

American Board of Radiology
GI Written Board Exam, Chair
December 2021-present

American College of Radiation Oncology (ACRO)
Annual Meeting Abstract Committee, Co-Chair
October 2021-present

American Society of Radiation Oncology (ASTRO)

Oligometastatic Disease Task Guidelines Task Force, Lead for Dose/Fractionation Key Question 4
September 2021-Present

American Society of Radiation Oncology (ASTRO)
eContouring Task Force Co-Chair
December 2020-present

Investigational Drug Steering Committee (IDSC)
Cancer Therapy Evaluation Program/ETCTN/NCI
June 2020-present

American Society of Radiation Oncology (ASTRO)
Small Cell Lung Cancer Task Guidelines Task Force, Lead for SBRT Key Question
7/2018-2/2020

Big Ten Cancer Research Consortium
Steering Committee
11/2017-present

Appropriateness Criteria/American College of Radiology
GI Committee Chair
5/2017-5/2021

American Society of Radiation Oncology (ASTRO)
Gastrointestinal Abstract Track Chair
10/2016-9/2019

American Board of Radiology
GI Section Oral Board Examiner
2/2015-present

National Cancer Institute, Radiation Research Program
GI Working Group Co-Chair
2/2015-present

Big Ten Cancer Research Consortium
GI Co-Chair
7/2014-3/2019

American Society of Radiation Oncology (ASTRO)
Annual Meeting Scientific Committee, Education Council
10/2012 – Present

American Society of Radiation Oncology (ASTRO)
Gastrointestinal Abstract Track, Vice Chair
11/2013- 6/2016

Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An American Society for Radiation Oncology (ASTRO) Best Practice Statement
4/2014

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

Radiological Society of North America (RSNA)
Member
2002 - Present

American Society of Women Radiologists (AAWR)
Member
2002 - Present

American Society of Clinical Oncology (ASCO)
Member
2006 - Present

American Society of Radiation Oncology
Member
2002 – Present

HONORS AND AWARDS

Inaugural Cancer Center Director's Award, Rutgers Cancer Institute of New Jersey, September 20, 2022, Research Grant for $50,000, Awarded for leadership, innovation, collaboration, dedication to RCINJ

Robert Wood Johnson University Hospital Recognition for Highest Press Gainey and Patient Feedback Ratings, July 2022

Expertscape Expert in Lung Cancer, December 9, 2021

Fellow of American Society of Radiation Oncology (FASTRO), Chicago, October 26, 2021

Award for Academic Excellence, Robert Wood Johnson Barnabas Health, November 29, 2018

Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award, May 2018

AAWR Mid-Career Development Award to attend AAMC Mid-Career Women Faculty Development Seminar 12/2/2017- 12/5/2017

Rutgers Biomedical and Health Sciences Women Leadership Symposium, June 1, 2017

Vitals Patients' Choice Award, 2016

Certificate for Excellence in Reviewing, Practical Radiation Oncology in Cooperation with the American Society for Radiation Oncology, 2016

Co-Editor of Special Issue for Translational Lung Cancer Research. Topic: Combining Radiation Therapy and Immunotherapy for Thoracic Malignancies, Invited in 5/2016

Best Doctors in America By Best Doctors, Inc., 1/2013-present

New Jersey's Top Doctors, New Jersey Savvy Magazine, 10/2011

Women in Leadership Program, "OASIS," Rutgers University, 2/2010-5/2010

Member, Cancer Institute of New Jersey, 12/2008-present

Johns Hopkins House Staff Council Distinguished Service Award, Johns Hopkins University School of Medicine, 6/2005

American College of Radiation Oncology, A. Robert Kagan Award in Palliative Medicine, 1/2005

Resident of the Month, Department of Internal Medicine, University of Maryland, January 2002

American Medical Women's Association Scholarship Achievement Award, Janet M. Glasgow Achievement Citation, 5/2001

Student Service Award, University of Maryland School of Medicine, 5/2001

Summer Research Grant, National Institutes of Health, 5/1998

Senatorial Scholarship Award, State of Maryland, 8/1997

Pre-Doctoral Intramural Research Training, National Institutes of Health, 8/1996

Intermediate Honors: Highest academic honor awarded to 3rd year students, University of Virginia 1/1996

Alpha Epsilon Delta Premedical Society, 1994-1996

Golden Key National Honor Society, 1996

Echols Scholar: Awarded to top 10% of undergraduates for high academic achievement and activities, University of Virginia, 1993-1996

BOARDS OF DIRECTORS/TRUSTEES POSITIONS: N/A

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES

CDMRP/Peer Reviewed Cancer Research Program/DOD Scientific Reviewer, September 28, 2021

CDMRP/Peer Reviewed Cancer Research Program/DOD Scientific Reviewer, February 2-3, 2021

CDMRP/Peer Reviewed Cancer Research Program/Reviewer, October 8-9, 2020

CDMRP/Peer Reviewed Cancer Research Program/DOD Scientific Reviewer, November 13-14, 2019

SERVICE ON MAJOR COMMITTEES:

A. International

1. NRG/NRG Foundation Communications Committee, August 2022-present
2. NRG Oncology Colorectal Cancer Committee, 1/2022-present
3. NRG Oncology Developmental Therapeutics Radiation Therapy Subcommittee, 12/2021-present
4. ECOG-ACRIN Radiation Oncology Committee, June 2020-present
5. ECOG-ACRIN Gastrointestinal Committee, June 2020-present
6. ASTRO Lung Blue Ribbon Panel, 11/2021-present
7. NRG Oncology GI Esophagogastric Working Group, 11/2021-present
8. ECOG-ACRIN, Radiation Oncology Committee, 3/2021-present
9. American Society of Radiation Oncology (ASTRO), Lung Track Selection Committee, March 2020-present
10. American Radium Society Scientific Program Committee, 6/2020-present
11. American Radium Society Appropriate Use Criteria Steering Committee; 7/2020-present
12. ARS Public Relations Committee, 6/2020-present
13. American Society of Radiation Oncology (ASTRO), Education Committee, 9/2019-present
14. ASTRO Health Equity, Inclusion and Diversity Committee Member, 7/2018-present
15. ASTRO Annual Meeting Abstract Committee, 10/2016-present

16. NRG Oncology, Protocol Monitoring Committee Member, 5/ 2018-present
17. American Society of Radiation Oncology (ASTRO) Gastrointestinal Malignancies, Abstract Reviewer for National Convention, 2010-2012, 2014-2016, 2021-present
18. American Society of Radiation Oncology (ASTRO) Government Relations Council, Congressional Relations Subcommittee, 10/2009 – 9/2010
19. Radiation Therapy Oncology Group (RTOG) Gastrointestinal Committee 6/2011 – 6/2014

B. National

1. NCI CTEP ETCTN Project Team (PTMA) Ipatasertib, Mentor to Dr. Malcolm Mattes, 7/2020-present
2. Investigational Drug Steering Committee Member, CTEP/NCI, 6/2020-present
3. Big Ten Cancer Research Consortium Steering Committee Member, 11/2017-present
4. Appropriateness Criteria/American College of Radiology, GI Committee Chair, May 2017-present
5. NCI CTEP PTMA Radium-223, Mentor to Dr. Jyoti Malhotra, 4/2018-present
6. NCI CTEP PTMA M3814, Subgroup member to Dr. Kristen Spencer, 2/2018-present
7. American Board of Radiology, GI Exam Board Member, 11/2014-present
8. ACR, In-Training Exam in Radiation Oncology, GI Section 2013-2021
9. American College of Radiology Appropriateness Criteria Committee GI Cancers Member, 4/2011 – 4/2017

C. Medical School/University

1. Leader, Radiation Oncology Disease Specific Group, Initiated Group, January 2022-present
2. Association for the Accreditation of Human Research Protection Programs (AAHRPP) Site Visit Participant, July 20, 2022
3. RCINJ Scientific Review Board Co-Chair, 6/2021-present
4. RCINJ Faculty Satisfaction-Steering Committee, 12/2020-present
5. RCINJ Faculty Retention Committee, Co-Chair, 12/2020-present
6. Rutgers Barnabas Health System Strategic Planning Research Subcommittee, 8/2020-11/2020; and Subcommittee on Biologic Effects of Disease
7. Clinical Trials Steering Committee, Rutgers Cancer Institute of NJ, 2/2020-present
8. RCINJ Human Research Oversight Committee (Data Safety Monitoring Board)Co-Chair, 1/2019-5/2021
9. Surgical Oncology Fellowship, Radiation Oncology Liaison, 7/2017-present
10. GI Disease Study Group, Co-Leader, Rutgers Cancer Institute of NJ, 2/2016-present
11. Phase I Developmental Therapeutics Team Member, 11/2015-present
12. RWJBH LCME Committee, RWJMS, 9/2016-present
13. RCINJ Human Research Oversight Committee (HROC) member, 1/2007 – 5/2021
14. RCINJ Scientific Review Board, 3/2008 – 6/2010, 9/2013-8/2015
15. Robert Wood Johnson Medical School Admissions Committee, 9/2010 – 6/2014
16. Medical School Admissions Committee Interviewer, University of Maryland School of Medicine, 9/1998 – 6/1999

D. Hospital

1. Medical Oncology Search Committees, Spring 2021, Fall 2021, Spring 2022
2. Medical Oncology Search Committee, 6/2016- 9/2016
3. Thoracic Surgical Oncology Search Committee, 1/2016-5/2016
4. CME Committee, 9/2016-present

E. Department

1. 4R Symposium Development Committee, Dept. of Radiation Oncology, 2018
2. Department of Radiation Oncology/CINJ, Director of Education, 1/ 2016-2/2018

3. Department of Radiation Oncology/CINJ Grand Rounds Planning Committee Director and CME Director, 8/2007- present

F. Editorial Boards
1. Gastro Hep Advances, Editorial Board, 11/2021-present
2. International Journal of Radiation Oncology, Biology, Physics, Deputy Editor, 10/2021-present
3. International Journal of Radiation Oncology, Biology, Physics, Senior Editor, GI Section, 9/2017-9/2020
4. International Journal of Radiation Oncology, Biology, Physics, Senior Associate Editor, GI Section, 2/2014-9/2017
5. Contemporary Radiation Oncology, Editorial Board 3/2015- present
6. Journal of Clinical Oncology Editorial Board, 2007-2013

G. AdHoc Reviewer
1. Radiotherapy Oncology, 2020-present
2. Clinical Cancer Research, 2018-present
3. Frontiers in Oncology, 2017-present
4. International Journal of Radiation Oncology Biology Physics, 2010 – Present
5. Journal of Clinical Oncology, 2007, 2013-present
6. Practical Radiation Oncology, 2012-present
7. Diseases of the Esophagus, 9/2012
8. Journal of Thoracic Disease, 12/2011 – 4/2012
9. American Journal of Clinical Oncology, 2009-present
10. Medical Oncology, 2008

SERVICE ON GRADUATE SCHOOL COMMITTEES:

Secretary
Johns Hopkins House Staff Council
July 2004 – June 2005

Delegate
Johns Hopkins House Staff Council
April 2003 – March 2004

Secretary, Class of 2001
University of Maryland School of Medicine
August 1997 – May 2001

SERVICE ON HOSPITAL COMMITTEES:

Policies & Procedures Committee
RWJBH
March 2022-present

Patient Satisfaction Committee
RWJBH
1/2022-present

Continuing Medical Education Committee
Robert Wood Johnson University Hospital
10/2006 – 1/2009

SERVICE TO THE COMMUNITY:

1. Novocure Platform Software Development, 4/2022-present
2. Data Safety Monitoring Board, Lantern Study, 2/2022-present

3. Clinical Adjudication Committee, Syntactx, Oversight for MRI Guided Pancreatic Cancer Clinical Trial, 3/2020-present
4. IMX Medical Reviewer, 11/2016-present
5. Data Safety Monitoring Board, University of Pennsylvania, PI Scott Halpern, Clinical Trial Evaluating Financial Incentives in RTOG 1308 Comparing Proton and Photon Therapy for Inoperable Locally Advanced Lung Cancer, 9/2015-present
6. CINJ-ECOG Audit at Overlook Hospital, 7/2014
7. CINJ-ECOG Audit at Morristown Memorial Hospital, 8/2011
8. Raritan Bay Medical Center Tumor Board, 8/ 27/2010
9. Raritan Bay Medical Center, 6/ 25/ 2010
10. Raritan Bay Medical Center, 2/26/ 2010
11. Raritan Bay Medical Center Tumor Board, 12/18/ 2009
12. Jersey Shore Medical Center Tumor Board, 10/15/ 2009
13. Bayshore Community Hospital Tumor Board, 5/ 6/ 2009
14. RWJUH Hamilton Tumor Board, 4/24/ 2009
15. CINJ- ECOG Audit at Morristown Memorial Hospital, 9/2008
16. Bayshore Community Hospital Tumor Board, 7/ 7/2008
17. Bayshore Community Hospital Tumor Board, 5/5/ 2008
18. Medical College at Princeton, 12/ 7/ 2006
19. Raritan Bay Medical Center, 12/15/2006
20. CentraState Hospital Tumor Board, 9/15/ 2006
21. Southern Ocean Community Hospital Tumor Board, 8/23/ 2006
22. Board Review Instructor and First Year Tutor, University of Maryland School of Medicine: 7/1998 – 6/1999

TEACHING RESPONSIBILITIES:

A. Lectures or Course Directorships

1. Rutgers Graduate School Course: Genomics in Cancer Therapeutics, The Landscape of Stage III NSCLC and Introduction to Radiation Oncology, Spring 2020, and Spring 2022
2. Department of Radiation Oncology Lecturer, Clinical Didactic Course for Radiation Oncology Residents
   Provide 6-10 one-hour lectures each academic year 2006-present
   - Locally Advanced Non-Small Cell Lung Cancer: Definitive Chemoradiation, 1 hour lecture given yearly
   - Role of RT in Colorectal Cancer, 1 hour lecture given yearly
   - Radiation Oncology, GI Mock Orals, 4 hours of exams given yearly
   - Gastric Cancer, 1 hour lecture given yearly
   - Anal Cancer, 1 hour lecture given yearly
   - Postoperative Therapy of Non-Small Cell Lung Cancer, 1 hour lecture given yearly
   - Management of Esophageal Cancer, 1 hour lecture given yearly
   - Management of Pancreatic Cancer, 1 hour lecture given yearly
3. Lecturer, Rutgers Graduate Course Radiobiology Course
   Provide 2 one-hour lectures each academic year 2006-present
   - Mechanisms of Normal Tissue Radiation Responses
   - Time Dose Fractionation
4. Lecturer, How to Design Combination Clinical Trials
   Medical and Radiation Oncology Fellows/Residents Statistical Course, 2007, 2009, 2011
5. Teaching of radiation oncology residents during intradepartmental weekly journal clubs, technical rounds, mock oral boards and case presentations
6. GI Surgery Rounds (twice per month): Case conference teaching of surgical and radiation oncology residents, medical oncology fellows 2008-2011

- Postoperative Management of Cholangiocarcinoma, 2010
- Radiation Oncology 101: Radiation Technologies 2010
- Management of Pancreatic Cancer in the Postoperative Setting, 2009
- GI Rounds Pancreas Cancer, 2009
- Management of Esophageal Cancer, 2008

7. Multidisciplinary Teaching Conference (once per month): Teaching case conference of surgical residents and radiation oncology residents 2009-2011
8. Lecturer, Medical Oncology Fellows
    - Radiation Oncology 101, 2007-2008, 2014-present
    - Esophageal Cancer
    - Updates in Radiation Oncology for Non-Small Cell Lung Cancer
    - Stomach and GE Junction
    - Radiation Therapy and Other GI Cancers

FACULTY MENTORSHIP:

Jyoti Malhotra, MD, Prior CINJ faculty, Current City of Hope, Lung Thoracic Oncologist

Kristen Spencer, MD, Prior CINJ faculty, Current NYU Langone, GI Medical Oncologist

Malini Patel, MD, CINJ Faculty, Hamilton, Thoracic and General Oncologist

Nisha Ohri, MD, CINJ Faculty, Breast Radiation Oncologist

Mridula George, MD, CINJ Faculty, Breast Radiation Oncologist

Nancy Chan, MD, Prior CINJ faculty, Current NYU Langone, Breast Medical Oncologist

Joseph Weiner, MD, Prior CINJ Faculty, Current private practice CNS Radiation Oncologist

Lara Hathout, MD, CINJ Faculty, Gyn/GU Radiation Oncologist

Matthew Deek, MD, CINJ Faculty, Lung/GI Radiation Oncologist

Anupama Chundury, MD, Prior CINJ Faculty, Current Loyola University CNS Radiation Oncologist

Laura Bond, MD, CINJ Faculty, General Radiation Oncologist Somerset Hospital

Malcolm Mattes, MD, CINJ Newark Faculty, Radiation Oncologist

Neha Amin, MD, Prior faculty at University of Maryland, Radiation Oncologist at AstraZeneca

Christopher Anker, MD, Faculty at University of Vermont, GI/Thoracic Radiation Oncologist

Irina Vergalasova, PhD, CINJ Faculty, Medical Physicist

Ke Nie, PhD, CINJ Faculty, Medical Physicist

Yin Zhang, PhD, CINJ Faculty, Medical Physicist

Meral Reyhan, PhD, CINJ Faculty, Medical Physicist

Nrusingh Biswal, PhD, Prior CINJ Faculty, Medical Physicist, Currently at University of Maryland

Jennifer Wei Zou, PhD, Prior CINJ Faculty, Medical Physicist, Currently at University of Pennsylvania

Julia Cornett, MD, RWJMS Faculty, Infectious Disease

SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:

Joshua Cinicola, PhD, Pharmacy Graduate Intern, GI Cancers Review, 2022

Zhou Jiang, B.S., RWJMS Master's in Clinical and Transitional Science Program, 9/2020-present

Shane Neibart, RWJMS MS-III, RWJMS Master's in Clinical and Transitional Science Program, 4/2020-present

Bin Gui, M.D., RWJMS Master's in Clinical and Transitional Science Program
12/2015-12/2016

Neil Newman, M.S. IV, RWJMS Master's in Clinical and Transitional Science Program
9/2014 – 8/2015

Caitlin Abidin Schonewolf, M.S. IV, RMJMS Master's in Clinical and Transitional Science Program
9/2011 – 8/2012

SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS:

Doaa Almeldin, M.D., Ph.D., Fulbright Scholar, 9/2019-6/2020

Swati Mamidanna, M.D., Research Fellow, 6/2019-present, current Rutgers Radiation Oncology resident

B. Research Training

Medical Students, Robert Wood Johnson Medical School

1. Samuel Workman, RWJMS MS-III, Review in Lung Cancer
2. Tomas Patrich, RWJMS MS-III, Endometrial Cancer
3. Sarah Oh, RWJMS MS-I, SBRT techniques in thoracic lesions, Summer 2022
4. Nikhil Patel, RWJMS MS-I, Thoracic Radiation and CBCT results, Summer 2022
5. Sean Hong, RWJMS MS-I, Rectal cancer and impact of chemotherapy, Summer 2021
6. Shari Bodofsky, MS-IV RWJMS, Inflammatory Bowel Disease and Radiation Therapy, 2021-2022, Matched at Yale Radiation Oncology
7. Daniella Portal, RWJMS MS-II, Resimulation and its Effects on Cardiopulmonary Toxicity in Lung Cancer, 2020-present
8. Shalom Rosenbaum, MS-II, Rectal Cancer Review, 2020
9. Krupa Jani, PhD, RWJMS MS-III, SEER analysis of other malignancies in anal cancer patients, 2019-2020; current Yale Radiation Oncology resident
10. Shane Neibert, RWJMS MS-III, Anorectal cancer quality of life, 2019; pancreatic cancer review, 2020; Radiation Pneumonitis Pharmacoepidemiology, matched at Harvard Radiation Oncology Program
11. Nikhil Yegya-Raman, MS-III lung cancer and radiation therapy cardiotoxicity outcomes and impact of novel radiation technologies; matched at University of Pennsylvania Radiation Oncology

12. Julian Sison, RWJMS MS-II, rectal cancer and impact of proton pump inhibitors on outcomes in patients treated with capecitabine and radiation therapy; Yale Internal Medicine
13. Dakim Gaines, RWMS MS-III, PhD, SBRT related tumor reduction, resident at Vanderbilt University in Radiation Oncology; matched at Vanderbilt Radiation Oncology
14. Christina Hadzitheoudorou, RWJMS MS-III Lung cancer and impact of tumor response to radiation therapy, 9/2015-present; Resident at RWJUH Internal Medicine, current faculty at RWJUH
15. Rosaline Ma, RWJMS MS-2, Leptomeningeal carcinomatosis, 6/2016-11/2017
16. Matthew Deek, RWJMS MS-3, Lung cancer and bone marrow toxicity, 9/2014-10/2017, matched at Johns Hopkins Radiation Oncology, current faculty at RCINJ
17. Neil Newman, RWJMS MS-3, Bone marrow toxicity with GI radiation, 9/2014-6/2016, current resident at Vanderbilt University in Radiation Oncology; matched at Vanderbilt Radiation Oncology, current faculty at UT San Antonio
18. Inaya Ahmed, RWJMS MS-3, Lung cancer and metformin, 9/ 2013-6/2014, matched at NYU Radiation Oncology
19. Eli Scher, Rowan DO SchoolMS-3, Lung cancer toxicities, 1/ 2014-10/2014, current resident at UC Cincinnati (Medical Student at Rowan School of Osteopathy), current radiation oncology faculty at Case Western
20. Andrew Chen, RWJMS MS-2, Lung cancer and nutrition, Summer 2014
21. Benjamin Benson, RWJMS MS-3, Prognostic Factors for Radioembolization, 10/2012-6/2013, current fellow at NYU in Interventional Radiology
22. Abdullah Rasheed, RWJMS MS-2: UMDNJ Summer Internship Program; lung tumor motion, Summer 2012 & Distinction in Research Program, Fall 2012-Spring 2013; Anesthesiology Resident SUNY Upstate
23. Jason Domegauer, New Jersey Medical School MS-2/PhD candidate, Pleural Effusions after radiation therapy for stage III lung cancer, 9/2012 – present, Radiation Oncology Resident NYU
24. Caitlin Abidin, RWJMS MS-4: Autophagy in Colorectal Cancer treated with Radiation, SIRSpheres retrospective review, 8/2011 – 6/2013, Resident in Radiation Oncology at University of Pennsylvania, current faculty at University of Michigan
25. Stephen Rosenberg, RWJMS MS-3: Lung cancer and organ motion with abdominal compression, Spring 2012, Resident in Radiation Oncology at University of Wisconsin, current faculty at Moffitt Cancer Center
26. Ahmet Tunceroglu, New Jersey Medical School MS-3: Dose painted IMRT in pancreatic cancer, 1/2012 – 6/2012, pain outcomes after radiotherapy, Rutgers Resident in Radiation Oncology Resident, Current faculty at University of Michigan
27. Grace Yang, MS-1, Renal Function after Upper Abdominal Radiation Therapy, 3/2013-6/2013,
28. Winston Wong, MS-2:UMDNJ Summer Internship Program; Autophagy in Chemoradiation for lung cancer, Summer 2012, Internal Medicine RWJUH
29. Matthew Listo, New Jersey Medical School MS-2: Pleural Effusions after Chemoradiation for Lung Cancer, Summer 2011, Tufts Medical Center Resident in Radiation Oncology
30. Sanaa Somalya, RWJMS MS-2: Lung Cancer tracking using Fluoroscopy and 4DCT during radiation therapy, Summer 2011, Resident in Internal Medicine at Thomas Jefferson
31. Shyamal Patel, RWJMS MS-4, Intensity Modulated Radiation Therapy for Rectal Cancer, 9/2009 – 12/2009, Resident in Radiation Oncology at Montefiore Medical Center
32. Kate Oususky, RWJMS MS-3.: ERCC1 and Local Failure in Pancreatic Cancer, 5/2009 – 5/2010; resident in Radiation Oncology at MD Anderson Hospital, current radiation oncologist in private practice
33. Bhavik Patel, RWJMS MS-2: Patterns of Failure in Treatment with SIR-Spheres, 5/2009 – 8/2009

34. Akshay Goel, RWJMS MS-3, Esophageal Cancer biomarkers for radiation therapy, 2009

RWJMS/RWJUH Residents

1. Jongmyung Kim, PGY-3, Immunotherapy & Radiation Therapy Bench & Bedside, April 2022-present
2. Karishma,Khullar, PGY-2, RWJBH Radiation Oncology Resident, rectal cancer review, 2019, ARRO educator of the Year Inequities, 2022
3. Andrew Zhang, MD, PGY-5 Radiation Oncology, Thresholds for vertebral body irradiation in esophageal cancer, 2017-2018
4. Shang-Jui Wang, MD, PhD, PGY-5 Radiation Oncology Rectal Cancer Review and Evaluation of Immunotherapy and Radiation, 2017-2018
5. Praveen Pendyala, MD, PGY-3, Radiation Oncology, Rectal Cancer Outcomes
6. Mutlay Sayan, MD, PGY-3, Radiation Oncology, Hepatoma Outcomes
7. Joseph Ho, MD, RWJUH internal medicine resident, esophageal cancer and impact of social support on outcomes, 2017
8. Robert Beck, M.D., PGY-5 Radiation Oncology, NCDB database analyses of non-small cell lung cancer and biliary tract tumors, 9/2015-10/2017, in practice
9. Parima Daroui, M.D, PGY-4, Radiation Oncology ERCC1 and Local Failure in Non-Small Cell Lung Cancer Survival in Oligometastatic Lung Cancer, Attending physician in Radiation Oncology at University of California, Irvine
10. Matthew Poppe, M.D, PGY-4, Radiation Oncology: Pancreatic IMRT and Tomotherapy, Attending physician in Radiation Oncology at University of Utah

Undergraduate and Post-Graduate Students, non-Medical Students

1. Milan Patel, East Brunswick High School, Lung Cancer Review, 2022
2. Huzaifa Piperdi, University of Michigan Undergraduate, Adaptive Radiation Therapy, 2020
3. Ahsan Ur-Khan, Rutgers RWJMS Capstone Program, CBCT use in non-small cell lung cancer, 2018-present
4. Christian Misdary, M.D., COVID-19 review, 2020
5. Diana Li, Rutgers Masters student, anal cancer outcomes
6. John Hobbs, Rutgers RWJMS Capstone Program, retrospective review of small cell lung cancer and thoracic radiation, 2016-2017
7. Michael Ryan, Rutgers RWJMS Capstone Program, retrospective review of small cell lung cancer and thoracic radiation, 2016-2017
8. Rekha Baby, MD, evaluation of response in lung cancer and radiation, 2013-2016
9. Morgan Levy, Lafayette University undergraduate student, Leptomeningeal carcinomatosis, 6/2016-12/2017
10. Brian Benenati, Rutgers RWJMS Capstone Program, evaluation of thoracic vertebral body radiation, 10/2015-11/2016, current Medical Student at Georgetown Medical School
11. Manpreet Kaur, Rutgers RWJMS Capstone Program, evaluation of pelvic bone marrow irradiation, 10/2015-11/2016
12. Bin Gui, post-doc, Radioembolization prognostic factors, 12/2015-12/2016
13. Liane Emerson, Duke undergraduate student, Electromechanical devices and radiotherapy, Summer 2015
14. Ajay Patel, Rutgers Preparatory Student, Factors Influencing Local Recurrence of Resected Pancreas Cancer, Summer 2012-6/2013, Undergraduate at University of Pennsylvania Mack Institute for Innovation
15. Abbas Syed Haider, RWJMS Capstone Program, Prognostic Significance of Tumor response during radiation therapy, 9/ 2012 – 6/2013, Rowan School of Osteopathy

16. Alson Wu, RWJMS Capstone Program, The Role of Induction Chemotherapy or outcome of stage III lung cancer patients, 9/2012 – 6/2013, Rowan School of Osteopathy
17. Alyssa Mancino, undergraduate student, RWJMS Summer Clinical Internship Program, Summer 2012
18. Marcus Hughes, Undergraduate Student, Minority Biomedical Careers Program/RWJMS, Summer 2012
19. Antonio Serrato, Undergraduate Student, Minority Biomedical Careers Program/RWJMS, Summer 2012
20. Jiten Kothadia, M.D.: Radiation Pneumonitis, Case Controlled Study, 6/2010 – 6/2012, Internal Medicine Brooklyn Hospital Center
21. Sairam Balasubramanian, Post-baccalaureate student: Lung and Pancreas Cancer Databases, 9/2009 – 8/2011, RWJMS Medical Student and Resident at University of Maryland Emergency Medicine
22. David Hernandez, Rutgers Undergraduate Student, Minority Biomedical Careers Program/RWJMS, Summer 2011
23. Marsophia Julemis, Rutgers Undergraduate Student, Minority Biomedical Careers Program/RWJMS, Summer 2011
24. Shweta Mehra, Rutgers Undergraduate Student, Rutgers Shadowing Program, Fall 2010 - Spring 2011
25. Adina Schwartz: RWJMS – Summer Clinical Internship Program, RWJMS ,Summer 2010
26. Samara Henry, Minority Biomedical Careers Program/RWJMS: Comparison of Fatigue Scores in Women Undergoing Partial Breast Irradiation, Summer 2010
27. Simone Henderson, Minority Biomedical Careers Program/RWJMS: Correlation of Thyroid Abnormalities in Pancreatic Cancer Patients, BCP program, Summer 2010
28. Svetlana Edylman, Rutgers Undergraduate student: Rutgers Shadowing Program, 1/ 2010 – 6/2010
29. Jessica Walker, Undergraduate Student, Minority Biomedical Careers Program/RWJMS: Pulse Oximetry in Radiation Pneumonitis, 6/2009 – 7/2009, Family Medicine Resident at Lancaster General
30. Victoria Torres, Undergraduate Student, Minority Biomedical Careers Program/RWJMS: Fatigue Scores in Patients Undergoing Breast Radiotherapy, 6/2009 – 7/2009

CLINICAL RESPONSIBILITIES:

1. 5-10 Consultations per week
2. 6-15 Follow-up's per week
3. 10-20 On-treatment visits per week
4. Gastrointestinal (GI) Tumor Study Group (weekly)
5. Thoracic Tumor Study Group (weekly)
6. Liver Tumor Study Group (weekly)
7. Thoracic and GI Research Meeting (weekly)
8. Gastrointestinal Malignancies: Esophageal cancer, gastric cancer, pancreatic cancer, liver neoplasms (metastases, hepatocellular carcinoma, cholangiocarcinoma), colorectal cancers
9. Thoracic Malignancies: Non-small cell lung cancer, small cell lung cancer
10. Initiation of Radiation Oncology Program of Liver Directed Therapy

GRANT SUPPORT:

A. Principal Investigator Investigator-Initiated Clinical Trials

1. A Phase 1 Trial of AN0025 with Chemoradiation Therapy in Stage III NSCLC Patients, Adlai Nortye, in progress

2. Preoperative ChemoRadiation And FOLFOXIRI To Escalate Complete Response for Rectal Cancer (CRAFTER for Rectal Cancer), RCINJ Institutional Funding, Additional Sponsor: Guardant Health
3. A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab, Sponsor: Merck& Co, Inc, (CINJ#71702); Direct Budget: $614,296, Indirect Budget: $184,288; Total Budget: $798,581; 2017-present
4. A Phase II Study of Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma, Sponsor: Beigene (CINJ#072105); Direct Budget: $330,346, Indirect Budget: $99,104, Total Budget $429,450; Additional Sponsor: Natera; ongoing
5. A Phase I Study of Pembrolizumab (MK-3475) and Concurrent Chemoradiation for Non-Small Cell Lung Cancer, accepted 8/2015 and activated 4/2015, Sponsor: Merck & Co., Inc. (CINJ#031507); Direct Budget: $169,182, Indirect Budget: $54,225, Total Budget: $223,407
6. Adaptive Radiation Planning in Non-Small Cell Lung Cancer, RCINJ Institutional Funding
7. Sensory Evaluation of a New Oral Nutrition Supplement in Patients at Risk for Mucositis: Taste, Nestle, September-November 2017
8. UMDNJ Foundation Grant, Phase I/II Radiotherapy Dose Escalation Study in Unresectable Pancreatic Cancer using a Simultaneous Intensity Modulated Boost, 06/01/09-05/31/10; Phase I/II Radiotherapy dose escalation for locally advanced pancreatic cancer, Rutgers Pilot Award

B. Co-Investigator, Completed Studies

1. Sirtex, Measurement of Pro-angiogenic Markers in Patients with hepatic metastases undergoing selective internal radiation therapy (SIRT), 07/22/2009 – 2012
2. Varian Medical Systems, Image registration between fluoroscopic image and (4D) CT images and its potential use in determination of radiation beam gating parameters, 09/01/08-08/30/09

C. Ongoing Clinical Trials as PI or co-PI

1. MK3475-799: (KEYNOTE-799) A Phase 2 Trial of Pembrolizumab in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (KEYNOTE-799), Lead PI; Direct Budget: $268, 337, Indirect Budget: 80,501, Total Budget: $348,839
2. NRG Oncology LU005: Limited Stage Small Cell Lung Cancer: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab, Radiation Oncology Co-Chair
3. A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non-Small Cell Lung Cancer (NSCLC)" (KEYNOTE-867), Radiation Oncology PI; Direct Budget: $316,205, Indirect Budget: $94,951, Total Budget: $411,156
4. Chemoradiation followed by Olaparib or Placebo Versus Chemoradiation followed by Durvalumab (MK7339-012/KEYLYNK-012), Radiation Oncology PI; Sponsor: Merck & Co, Inc.; Direct Budget: $1,219,399, Indirect Budget: $365,820, Total Budget: $1,585,219
5. Phase III Trial of Concurrent chemoradiation with Pembrolizumab followed by Olarparib and Olaparib Placebo compared to Chemoradiation for Limited Stage Small Cell Lung Cancer MK-7339-013/KEYLYNK-013), Sponsor: Merck &Co, Inc; Direct Budget: $1,022,601, Indirect Budget: $306,780, Total Budget: $1,329,382

6. Phase II Trial of Radium-223 in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer (CTEP sponsored study via Project Team Management Group (PTMA)) –Senior mentor to Dr. Jyoti Malhtora, Radiation Oncology Chair
7. A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies—CTEP Sponsored Study, Radiation Oncology Mentor to Dr. Kristen Spencer & Radiation Chair
8. A Phase I Trial of Atezolizumab and Varlilumab in Combination with Radiation in Patients with Metastatic NSCLC—Institutional Study, Co-PI to Dr. Malhotra
9. CCC19, COVID-19 and Cancer Consortium, Institutional PI, 6/2020-present

D. Institutional PI for Multi-Institutional/NCI Cooperative Group Sponsored Studies
1. A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)
2. ECOG-ACRIN 5181: Consolidative +/- Concurrent Durvalumab with Chemoradiation for St III NSCLC
3. A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174)
4. ORIEN 20PRJ056MAR: Radiogenomic prognostic biomarker development for non-small cell lung cancer patients
5. ECOG-ACRIN 2165: Nivolumab after Chemoradiation for High Risk Anal Cancer
6. BTCRC 16-081: Consolidative Nivolumab vs Ipilimumab + Nivolumab for Stage III NSCLC after ChemoRT
7. SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
8. NRG GI002 TNT in Rectal Cancer
9. MEDI4736 and Tremelimumab alone or in combination with radiation in mCRC and NSCLC (CTEP 10021)
10. CALGB 80803: Phase II Trial of PET Scan Directed Therapy in Esophageal Cancer
11. RTOG 0822: A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing IMRT in Combination with Capecitabine and Oxaliplaitin for Patients with Locally Advanced Rectal Cancer; Jabbour
12. RTOG 1306, A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer
13. Hoosier Oncology Group, Consolidation Pembrolizumab Following Chemoradiation in Patients with Inoperable/Unresectable NSCLC LUN14-179
14. Phase I Study of REGN2810 (Anti-PD1) in Patients with Advanced Malignancies
15. ADXS11-001 and Chemoradiotherapy for Anal Cancer
16. A021501 Preoperative Chemotherapy +/- Radiation Therapy for Borderline Resectable Pancreatic Cancer

E. Pending/Awarded NIH Grants
1. NCI UM1 Grant (UM1CA186644-06): North American Star Consortium, PI for Rutgers Affiliated Organization to Princess Margaret Hospital, 5/5/20-2/28/2023
2. NCI UM1 Grant (5UM1CA186716) Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics, 3/2019-5/2020, NCE through 2/28/2021
3. Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy and Immunotherapy (submitted, pending review) Sub-award with Thomas Jefferson University– prime sponsor: NIH Period of performance: 7/1/2020 – 6/30/2025 Total funds requested: $386,087 Level of effort: 1.2 months of 10% each year for the 5-year proposed duration; pending
4. STTR/SBIR Grant: Quantitative Radiology Solutions; Automatic Object Contouring Methods and Software for Radiotherapy Planning No: 2R42CA199735-02; Institutional PI with total of 17% effort, Jabbour: 5.54% effort; $74,363

5. Cancer Center Support Grant P30 P30CA072720, NCI-NIH, Annual Direct Cost: $1,983,506, Co-Chair of HROC, 5% effort, 03/01/2019 – 02/29/2024

F. Retrospective IRB Approved Studies
1. Analysis of Patients with Oligometastatic NSCLC Treated with Combined Chemo-Radiotherapy
2. Analysis of BCCIP Protein and PTEN Protein Levels in Pancreatic Adenocarcinoma Tumor Samples
3. Correlation of ERCC1 in Local Recurrence after Radiotherapy for NSCLC and Pancreatic Cancer
4. Outcomes in Colorectal Patients with Liver Metastases following Surgery or Hepatic Arterial Infusion
5. The COVID-19 and Cancer Consortium (CCC19) Registry
6. Validation of Claims-Based Algorithms for Identifying Non-Infectious Pneumonitis in Cancer Patients
7. Bone Marrow Toxicity after Radiation Therapy
8. Retrospective Review of Efficacy and Toxicity for Upper Abdominal Cancers
9. Evaluation of AAR-RT methods and software for automated OAR contouring in H&N and thorax for RT plan
10. Chart Review of COVID-19 patients
11. Chart Review of Bone Metastases Treated with Radiation
12. Immunotherapy Chart Review
13. Anorectal Radiation Therapy
14. Lung Cancer Outcomes with Radiation Therapy
15. Non-Infectious Pneumonitis in Stage IV Non-Small Cell Lung Cancer
16. Factors contributing to pathological complete response in esophageal cancer

G. Non-Accrued Trials
1. Phase I Study of BMS-663513 + Radiation or Chemoradiation in Non-Small Cell Lung Carcinoma
2. PET/CT adapted radiotherapy for Stage III NSCLC, rtog 1106
3. Sublobar resection vs SABR
4. Phase II Preoperative Chemoradiation with Hydroxychloroquine for Rectal Cancer
5. Phase I/II Study of SGX201 to prevent radiation enteritis in rectal cancer patients
6. JHU: Phase II Allogeneic GM-CSF Vaccine (GVAX), SBRT and GTX for Pancreatic Cancer
7. Sequential Stereotactic Body Radiation Therapy and Microwave Ablation for Unresectable Liver Cancers

PUBLICATIONS:

A. Refereed Original Article in Journal

1. Kumar R, Tchelebi L, Anker CJ, Sharma N, Bianchi NA, Dragovic J, Goodman KA, Herman JM, Jiang Y, Jones WE 3rd, Kennedy TJ, Lee P, Kundranda M, Russo S, Small W, Suh WW, Yee N, **Jabbour SK**. American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma: Systematic Review and Guidelines. Am J Clin Oncol. 2022 Aug 10. doi: 10.1097/COC.0000000000000930. Epub ahead of print. PMID: 35947781.

2. Nie K, Hu P, Zheng J, Zhang Y, Yang P, **Jabbour SK**, Yue N, Dong X, Xu S, Shen B, Niu T, Hu X, Cai X, Sun J. Incremental Value of Radiomics in 5-Year Overall Survival Prediction for Stage II-III Rectal Cancer. Front Oncol. 2022 Jun 30;12:779030. doi: 10.3389/fonc.2022.779030. PMID: 35847948; PMCID: PMC9279662.

3. Udupa JK, Liu T, Jin C, Zhao L, Odhner D, Tong Y, Agrawal V, Pednekar G, Nag S, Kotia T, Goodman M, Wileyto EP, Mihailidis D, Lukens JN, Berman AT, Stambaugh J, Lim T, Chowdary R, Jalluri D, **Jabbour SK**, Kim S, Reyhan M, Robinson CG, Thorstad WL, Choi JI, Press R, Simone CB 2nd, Camaratta J, Owens S, Torigian DA. Combining natural and artificial intelligence for robust automatic anatomy segmentation: Application in neck and thorax auto-contouring. Med Phys. 2022 Jul 14. doi: 10.1002/mp.15854. Epub ahead of print. PMID: 35833287.

4. Malhotra J, Ryan B, Patel M, Chan N, Guo Y, Aisner J, **Jabbour SK**, Pine S. Clinical outcomes and immune phenotypes associated with *STK11* co-occurring mutations in non-small cell lung cancer. J Thorac Dis. 2022 Jun;14(6):1772-1783. doi: 10.21037/jtd-21-1377. PMID: 35813711; PMCID: PMC9264081.

5. Jethwa KR, Neibart SS, Truty MJ, **Jabbour SK**, Hallemeier CL. Patterns of Recurrence After Primary Local Therapy for Pancreatic Ductal Adenocarcinoma - A Critical Review of Rationale and Target Delineation for (Neo)Adjuvant Radiation Therapy. Pract Radiat Oncol. 2022 Jun 17:S1879-8500(22)00196-5. doi: 10.1016/j.prro.2022.06.004. Epub ahead of print. PMID: 35718073.

6. Liu Q, Xu JY, Xu YH, Chen M, Deng LC, Wu JP, Zhou T, Zhang LQ, Tan J, Pu XX, Shang YL, Hua J, Li YQ, Cai W, Gu YL, Peng XC, Chan PC, **Jabbour SK**, Nam HS, Hua D. Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial. Transl Lung Cancer Res. 2022 May;11(5):832-844. doi: 10.21037/tlcr-22-313. PMID: 35693282; PMCID: PMC9186180.

7. **Jabbour SK**, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L, Morgensztern D, Shentu Y, Kim SJ, Souza F, Reck M. Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2022 Apr 29:S1525-7304(22)00066-3. doi: 10.1016/j.cllc.2022.04.003. Epub ahead of print. PMID: 35618629.

8. Rimner A, Lai WV, Califano R, **Jabbour SK**, Rudin CM, Faivre-Finn C, Cho BC, Kato T, Yu J, Chafin W, Yu L, Zhao B, Byers L. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2022 Jul;23(5):e325-e329. doi: 10.1016/j.cllc.2022.04.005. Epub 2022 Apr 29. PMID: 35613997.

9. Sharma NK, Kappadath SC, Chuong M, Folkert M, Gibbs P, **Jabbour SK**, Jeyarajah DR, Kennedy A, Liu D, Meyer JE, Mikell J, Patel RS, Yang G, Mourtada F. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. Brachytherapy. 2022 May 19:S1538-4721(22)00072-1. doi: 10.1016/j.brachy.2022.04.004. Epub ahead of print. PMID: 35599080.

10. Fu J, Reid SA, French B, Hennessy C, Hwang C, Gatson NT, Duma N, Mishra S, Nguyen R, Hawley JE, Singh SRK, Chism DD, Venepalli NK, Warner JL, Choueiri TK, Schmidt AL, Fecher LA, Girard JE, Bilen MA, Ravindranathan D, Goyal S, Wise-Draper TM, Park C, Painter CA, McGlown SM, de Lima Lopes G Jr, Serrano OK, Shah DP; COVID-19 and Cancer Consortium (CCC19). Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. JAMA Netw Open. 2022 Mar 1;5(3):e224304. doi: 10.1001/jamanetworkopen.2022.4304. PMID: 35344045; PMCID: PMC8961318.

11. Neibart SS, Mamidanna S, Chundury A, Sayan M, Alexander HR, August DA, Berim LD, Boland PM, Grandhi MS, Gulhati P, Hochster HS, Langan RC, Spencer KR, Kennedy TJ, Deek MP, **Jabbour SK**. Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. J Gastrointest Oncol. 2021 Dec;12(6):2557-2566. doi: 10.21037/jgo-21-503. PMID: 35070387; PMCID: PMC8748032.

12. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, Hubbard J, Arnold SM, Abbruzzese JL, **Jabbour SK**, Uboha NV, Stephans KL, Johnson JM, Park H, Villaruz LC, Sharon E, Streicher H, Ahmed MM, Lyon H, Cibuskis C, Lennon N, Jhaveri A, Yang L, Altreuter J, Gunasti L, Weirather JL, Mak RH, Awad MM, Rodig SJ, Chen HX, Wu CJ, Monjazeb AM, Hodi FS. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022 Jan 13:S1470-2045(21)00658-6. doi: 10.1016/S1470-2045(21)00658-6. Epub ahead of print. PMID: 35033226.

13. Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N., Mishra, S., Nguyen, R. H., Reid, S. A., Serrano, O. K., Singh, S., Venepalli, N. K., Bakouny, Z., Bashir, B., Bilen, M. A., Caimi, P. F., Choueiri, T. K., Dawsey, S. J., Fecher, L. A., Flora, D. B., … COVID-19 and Cancer Consortium (CCC19) (2022). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. *JAMA network open*, *5*(1), e2142046. https://doi.org/10.1001/jamanetworkopen.2021.42046

14. Piperdi H, Portal D, Neibart SS, Yue NJ, **Jabbour SK**, Reyhan M. Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field. Front Oncol. 2021 Nov 29;11:770382. doi: 10.3389/fonc.2021.770382. PMID: 34912715; PMCID: PMC8666420.

15. Zhou B, Li Q, Qin L, Li Z, Jin K, Dai J, Zhu Y, Yang Y, **Jabbour SK**, Tartarone A, Ng CSH, Navarro A, Pompili C, Jiang G. Octogenarians may benefit from stage-specific small cell lung cancer treatment. Transl Lung Cancer Res. 2021 Oct;10(10):3973-3982. doi: 10.21037/tlcr-21-839. PMID: 34858785; PMCID: PMC8577968.

16. Wen J, Chen J, Chen D, **Jabbour SK**, Xue T, Guo X, Ma H, Ye F, Mao Y, Shu J, Liu Y, Lu X, Zhang Z, Chen Y, Fan M. Comprehensive analysis of prognostic value of lymph node classifications in esophageal squamous cell carcinoma: a large real-world multicenter study. Ther Adv Med Oncol. 2021 Nov 5;13:17588359211054895. doi: 10.1177/17588359211054895. PMID: 34777583; PMCID: PMC8573486.

17. Mondal A, NeMoyer R, Vora M, Napoli L, Syed Z, Langenfeld E, Jia D, Peng Y, Gilleran J, Roberge J, Rongo C, **Jabbour SK**, Langenfeld J. Bone morphogenetic protein receptor 2 inhibition destabilizes microtubules promoting the activation of lysosomes and cell death of lung cancer cells. Cell Commun Signal. 2021 Sep 25;19(1):97. doi: 10.1186/s12964-021-00743-w. PMID: 34563224; PMCID: PMC8466694.

18. Monjazeb AM, Giobbie-Hurder A, Lako A, Thrash EM, Brennick RC, Kao KZ, Manuszak C, Gentzler RD, Tesfaye A, **Jabbour SK**, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon HJ, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjatic S, Maverakis E, Marusina AI, Merleev AA, Severgnini M, Pfaff KL, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig SJ, Hodi FS, Schoenfeld JD. Correction: A Randomized Trial of Combined PD-L1 and

CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Sep 1;27(17):4940. doi: 10.1158/1078-0432.CCR-21-2698. Erratum for: Clin Cancer Res. 2021 May 1;27(9):2470-2480. PMID: 34470811.

19. Neibart SS, Portal DE, Malhotra J, **Jabbour SK**, Roy JA, Strom BL. Validation of a Claims-Based Algorithm for Identifying Non-Infectious Pneumonitis in Patients Diagnosed with Lung Cancer. Pharmacoepidemiol Drug Saf. 2021 Aug 11. doi: 10.1002/pds.5339. Epub ahead of print. PMID: 34378828.

20. Wen J, Wei Y, **Jabbour SK**, Xu T, Wang Y, Chen J, Wang J, Hu C, Su F, Fan M, Zhang Z, Lu X. Comprehensive analysis of prognostic value of lymph node staging classifications in patients with head and neck squamous cell carcinoma after cervical lymph node dissection. Eur J Surg Oncol. 2021 Jul;47(7):1710-1717. doi: 10.1016/j.ejso.2021.01.020. Epub 2021 Jan 30. PMID: 33549377.

21. Deek MP, Yegya-Raman N, Daroui P, Balasubramanian S, Malhotra J, Moore D, Patel M, Wang SJ, Aisner J, **Jabbour SK**. Overexpression of excision repair cross-complementing 1 gene associates with higher risk of therapeutic failure after definitive chemoradiation for unresectable non-small cell lung cancer. Ann Palliat Med. 2021 Jun 26:apm-21-182. doi: 10.21037/apm-21-182. Epub ahead of print. PMID: 34263627.

22. Tunceroglu AS, Gui B, Lu SE, Sison J, Parikh R, Goyal S, Haffty BG, Kim S, **Jabbour SK**. Does kV Image Guidance for Bone Metastases Improve Pain Control? Front Oncol. 2021 Jun 17;11:627282. doi: 10.3389/fonc.2021.627282. PMID: 34221957; PMCID: PMC8247921.

23. Thompson MA, Henderson JP, Shah PK, Rubinstein SM, Joyner MJ, Choueiri TK, Flora DB, Griffiths EA, Gulati AP, Hwang C, Koshkin VS, Papadopoulos EB, Robilotti EV, Su CT, Wulff-Burchfield EM, Xie Z, Yu PP, Mishra S, Senefeld JW, Shah DP, Warner JL; COVID-19 and Cancer Consortium. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1799. Epub ahead of print. PMID: 34137799.

24. **Jabbour SK**, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4. doi: 10.1001/jamaoncol.2021.2301. Epub ahead of print. PMID: 34086039.

25. Jamorabo DS, Deek MP, Yom SS, Rehman H, Zietman AL, Motwani SB, Briggs WM, Kim S, Chang DT, **Jabbour SK**. Can sex and seniority predict the quality of a journal reviewer's manuscript critique? Int J Radiat Oncol Biol Phys. 2021 May 24:S0360-3016(21)00653-2. doi: 10.1016/j.ijrobp.2021.05.111. Epub ahead of print. PMID: 34044095.

26. Xu F, Zeng Z, Yan B, Fu Y, Sun Y, Yang G, Tu L, Watanabe S, **Jabbour SK**, Bravaccini S, Fanini F, Zhou J, Shen Y. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. Transl Lung Cancer Res. 2021 Apr;10(4):1819-1828. doi: 10.21037/tlcr-21-79. PMID: 34012795; PMCID: PMC8107742.

27. Jani KS, Lu SE, Murphy JD, Romesser PB, Jethwa KR, Li D, Chundury A, Wu AJ, Hathout L, Hallemeier CL, **Jabbour SK**. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis. Cancer Med. 2021 May 7. doi: 10.1002/cam4.3909. Epub ahead of print. PMID: 33960690.

28. Ho JK, Gui B, Yoon J, Zhang Q, Manne SL, **Jabbour SK**. Influence of Caregiver Presence During Physician Office Visits on Patients Undergoing Chemoradiation Therapy for Esophageal Cancer. Adv Radiat Oncol. 2021 Jan 16;6(2):100649. doi: 10.1016/j.adro.2021.100649. PMID: 33912737; PMCID: PMC8071720.

29. Khullar K, Dhawan ST, Nosher J, Jabbour SK. Fiducial marker migration following computed tomography-guided placement in the liver: a case report. AME Case Rep. 2021 Apr 25;5:15. doi: 10.21037/acr-20-153. PMID: 33912804; PMCID: PMC8060155.

30. Khan AR, Misdary C, Yegya-Raman N, Kim S, Narayanan N, Siddiqui S, Salgame P, Radbel J, Groote F, Michel C, Mehnert J, Hernandez C, Braciale T, Malhotra J, Gentile MA, **Jabbour SK**. Montelukast in Hospitalized Patients Diagnosed with COVID-19. J Asthma. 2021 Feb 12:1-13. doi: 10.1080/02770903.2021.1881967. Epub ahead of print. PMID: 33577360.

31. Monjazeb AM, Giobbie-Hurder A, Lako A, Thrash EM, Brennick R, Kao KZ, Manuszak C, Gentzler RD, Tesfaye A, **Jabbour S**, Alese OB, Rahma OE, Cleary JM, Sharon E, Mamon H, Cho M, Streicher H, Chen HX, Ahmed MM, Mariño-Enríquez A, Kim-Schulze S, Gnjatic S, Maverakis E, Marusina A, Merleev A, Severgnini M, Pfaff K, Lindsay J, Weirather JL, Ranasinghe S, Spektor A, Rodig S, Hodi FS, Schoenfeld JD. A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Feb 10:clincanres.4632.2020. doi: 10.1158/1078-0432.CCR-20-4632. Epub ahead of print. PMID: 33568343.

32. Wen J, Wei Y, **Jabbour SK**, Xu T, Wang Y, Chen J, Wang J, Hu C, Su F, Fan M, Zhang Z, Lu X. Comprehensive analysis of prognostic value of lymph node staging classifications in patients with head and neck squamous cell carcinoma after cervical lymph node dissection. Eur J Surg Oncol. 2021 Jan 30:S0748-7983(21)00050-0. doi: 10.1016/j.ejso.2021.01.020. Epub ahead of print. PMID: 33549377.

33. Jhawar SR, Palmer JD, Wang SJ, Bitterman D, Klamer B, Huynh-Le M, Chung C, Ohri N, Stover DG, Lustberg MB, Mishra S, Warner J, **Jabbour S**, Goyal S; CCC19 Radiation Oncology Group. The COVID-19 & Cancer Consortium (CCC19) and Opportunities for Radiation Oncology. Adv Radiat Oncol. 2021 Jan-Feb;6(1):100614. doi: 10.1016/j.adro.2020.10.026. Epub 2020 Dec 24. PMID: 33521393; PMCID: PMC7834122.

34. Greco SH, August DA, Shah MM, Chen C, Moore DF, Masanam M, Turner AL, **Jabbour SK**, Javidian P, Grandhi MS, Kennedy TJ, Alexander HR, Carpizo DR, Langan RC. Neoadjuvant therapy is associated with lower margin positivity rates after Pancreaticoduodenectomy in T1 and T2 pancreatic head cancers: An analysis of the National Cancer Database. Surg Open Sci. 2020 Dec 16;3:22-28. doi: 10.1016/j.sopen.2020.12.001. PMID: 33490937; PMCID: PMC7807160.

35. Zhang Y, **Jabbour SK**, Zhang A, Liu B, Yue NJ, Biswal NC. Proton beam therapy can achieve lower vertebral bone marrow dose than photon beam therapy during chemoradiation therapy of esophageal cancer. Med Dosim. 2021 Jan 13:S0958-3947(20)30166-7. doi: 10.1016/j.meddos.2020.12.003. Epub ahead of print. PMID: 33454170.

36. Miccio JA, Talcott WJ, Patel T, Park HS, Cecchini M, Salem RR, Khan SA, Stein S, Kortmansky JS, Lacy J, Narang A, Herman J, **Jabbour SK**, Hallemeier CL, Johung K, Jethwa KR. Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis. Clin Transl Radiat Oncol. 2020 Dec 16;27:15-23. doi: 10.1016/j.ctro.2020.12.003. PMID: 33392398; PMCID: PMC7772693.

37. **Jabbour SK**, Williams TM, Sayan M, Miller ED, Ajani JA, Chang AC, Coleman N, El-Rifai W, Haddock M, Ilson D, Jamorabo D, Kunos C, Lin S, Liu G, Prasanna PG, Rustgi AK, Wong R, Vikram B, Ahmed M. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst. 2020 Dec 22:djaa195. doi: 10.1093/jnci/djaa195. Epub ahead of print. PMID: 33351071.

38. COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org; COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell. 2020 Dec 14;38(6):761-766. doi: 10.1016/j.ccell.2020.10.022. Epub 2020 Oct 29. PMID: 33176160; PMCID: PMC7598547.

39. Markowitz P, Patel M, Groisberg R, Aisner J, **Jabbour SK**, De S, Ganesan S, Malhotra J. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treat Res Commun. 2020 Nov 3;25:100232. doi: 10.1016/j.ctarc.2020.100232. Epub ahead of print. PMID: 33166854.

40. Hathout L, Ennis R, Mattes MD, Wagman R, Grann A, **Jabbour SK**, Singh R, Yue N, Haffty B, Vergalasova I. The Impact of COVID-19 on brachytherapy during the pandemic: a Rutgers-Robert Wood Johnson Barnabas Health multi-site experience. Adv Radiat Oncol. 2020 Nov 2:100600. doi: 10.1016/j.adro.2020.10.013. Epub ahead of print. PMID: 33163697; PMCID: PMC7605726.

41. Wang SJ, Khullar K, Kim S, Yegya-Raman N, Malhotra J, Groisberg R, Crayton SH, Silk AW, Nosher JL, Gentile MA, Mehnert JM, **Jabbour SK**. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. J Immunother Cancer. 2020 Oct;8(2):e000889. doi: 10.1136/jitc-2020-000889. PMID: 33020239; PMCID: PMC7537331.

42. Yegya-Raman N, Cao CD, Hathout L, Girda E, Richard SD, Rosenblum NG, Taunk NK, **Jabbour SK**. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review. Gynecol Oncol. 2020 Sep 8:S0090-8258(20)33808-7. doi: 10.1016/j.ygyno.2020.08.010. Epub ahead of print. PMID: 32917412.

43. Rischin D, Gil-Martin M, González-Martin A, Braña I, Hou JY, Cho D, Falchook GS, Formenti S, **Jabbour S**, Moore K, Naing A, Papadopoulos KP, Baranda J, Fury W, Feng M, Stankevich E, Li J, Yama-Dang NA, Yoo SY, Lowy I, Mathias M, Fury MG. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 Sep 8:S0090-8258(20)33827-0. doi: 10.1016/j.ygyno.2020.08.026. Epub ahead of print. PMID: 32917410.

44. Anker CJ, Dragovic J, Herman JM, Bianchi NA, Goodman KA, Jones WE 3rd, Kennedy TJ, Kumar R, Lee P, Russo S, Sharma N, Small W, Suh WW, Tchelebi L, **Jabbour SK**. Executive Summary of the American Radium Society™ (ARS)

Appropriate Use Criteria (AUC) for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. Int J Radiat Oncol Biol Phys. 2020 Aug 25:S0360-3016(20)34163-8. doi: 10.1016/j.ijrobp.2020.08.050. Epub ahead of print. PMID: 32858113.

45. Thomson DJ, Yom SS, Saeed H, El Naqa I, Ballas L, Bentzen SM, Chao ST, Choudhury A, Coles CE, Dover L, Guadagnolo BA, Guckenberger M, Hoskin P, **Jabbour SK**, Katz MS, Mukherjee S, Rembielak A, Sebag-Montefiore D, Sher DJ, Terezakis SA, Thomas TV, Vogel J, Estes C. Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):379-389. doi: 10.1016/j.ijrobp.2020.06.054. Epub 2020 Aug 11. PMID: 32798063.

46. Shah MM, NeMoyer RE, Greco SH, Chen C, Moore DF, Grandhi MS, Langan RC, Kennedy TJ, Javidian P, **Jabbour SK**, Alexander HR, August DA, Carpizo DR. Subcategorizing T1 Staging in Pancreatic Adenocarcinoma Predicts Survival in Patients Undergoing Resection: An Analysis of the National Cancer Database. J Pancreat Cancer. 2020 Jul 14;6(1):64-72. doi: 10.1089/pancan.2019.0017. PMID: 32766509; PMCID: PMC7404823.

47. Durm GA, **Jabbour SK**, Althouse SK, Liu Z, Sadiq AA, Zon RT, Jalal SI, Kloecker GH, Williamson MJ, Reckamp KL, Langdon RM, Kio EA, Gentzler RD, Adesunloye BA, Harb WA, Walling RV, Titzer ML, Hanna NH. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179. Cancer. 2020 Jul 22. doi: 10.1002/cncr.33083. Epub ahead of print. PMID: 32697352.

48. Gaines DK, Yegya-Raman N, Kim S, Simone CB 2nd, Theodorou Ross C, Deek MP, Lam S, Feigenberg SJ, Osorio B, Nie K, Zou W, Patel M, Malhotra J, Langenfeld J, Aisner J, **Jabbour SK**. Tumor volume reduction evaluated by cone beam computed tomography during stereotactic body radiotherapy for early stage non-small cell lung cancer. J Thorac Dis. 2020 May;12(5):2482-2488. doi: 10.21037/jtd.2020.03.46. PMID: 32642155; PMCID: PMC7330363.

49. Shah MM, Meyer BI, Rhee K, NeMoyer RE, Lin Y, Tzeng CD, **Jabbour SK**, Kennedy TJ, Nosher JL, Kooby DA, Maithel SK, Carpizo DR. Conditional survival analysis of hepatocellular carcinoma. J Surg Oncol. 2020 Jun 10. doi: 10.1002/jso.26049. Epub ahead of print. PMID: 32524634.

50. Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, **Jabbour SK**, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2020 May-Jun;10(3):158-173. doi: 10.1016/j.prro.2020.02.009. Epub 2020 Mar 23. PMID: 32222430.

51. **Jabbour SK**, Berman AT, Decker RH, Lin Y, Feigenberg SJ, Gettinger SN, Aggarwal C, Langer CJ, Simone CB 2nd, Bradley JD, Aisner J, Malhotra J. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2020 Feb 20. doi: 10.1001/jamaoncol.2019.6731. Epub ahead of print. PMID: 32077891.

52. Malhotra J, **Jabbour SK**, Pine S. Impact of surveillance frequency on survival in non-small cell lung cancer (NSCLC) survivors. Transl Lung Cancer Res. 2019

Dec;8(Suppl 4):S347-S350. doi: 10.21037/tlcr.2019.05.04. PMID: 32038912; PMCID: PMC6987361.

53. Sayan M, Ohri N, Lee A, Abou Yehia Z, Gupta A, Byun J, **Jabbour SK**, Wagman R, Haffty BG, Weiner J, Kim S. The Impact of Formal Mentorship Programs on Mentorship Experience Among Radiation Oncology Residents From the Northeast. Front Oncol. 2019 Dec 4;9:1369. doi: 10.3389/fonc.2019.01369. PMID: 31867278; PMCID: PMC6904328.

54. Wang X, Ma C, Davis R, Parikh RR, **Jabbour SK**, Haffty BG, Yue NJ, Nie K, Zhang Y. A novel approach to Verify air gap and SSD for proton radiotherapy using surface imaging. Radiat Oncol. 2019 Dec 11;14(1):224. doi: 10.1186/s13014-019-1436-4. PMID: 31829246.

55. NeMoyer R, Mondal A, Vora M, Langenfeld E, Glover D, Scott M, Lairson L, Rongo C, Augeri DJ, Peng Y, **Jabbour SK**, Langenfeld J. Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein. Cell Commun Signal. 2019 Nov 19;17(1):150. doi: 10.1186/s12964-019-0469-5. PMID: 31744505; PMCID: PMC6862756.

56. Malhotra J, **Jabbour S**, Orlick M, Riedlinger G, Guo Y, White E, Aisner J. Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). Cancer Treat Res Commun. 2019 Sep 5;21:100158. doi: 10.1016/j.ctarc.2019.100158. [Epub ahead of print] PubMed PMID: 31521049.

57. Russo S, Anker CJ, Abdel-Wahab M, Azad N, Das P, Dragovic J, Goodman KA,Herman JM, Jones W 3rd, Kennedy T, Konski A, Kumar R, Lee P, Patel NM, Sharma N, Small W, Suh WW, **Jabbour SK**. Executive Summary of the ARS Appropriate Use Criteria for Local Excision in Rectal Cancer. Int J Radiat Oncol Biol Phys. 2019 Aug 21. pii: S0360-3016(19)33654-5. doi: 10.1016/j.ijrobp.2019.08.020. [Epub ahead of print] Review. PubMed PMID: 31445109

58. Yegya-Raman N, Aisner J, Kim S, Sayan M, Li D, Langenfeld J, Patel M, Malhotra J, **Jabbour SK**. Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. Adv Radiat Oncol. 2019 Mar 22;4(3):541-550. doi:10.1016/j.adro.2019.03.005. eCollection 2019 Jul-Sep. PubMed PMID: 31360811;PubMed Central PMCID: PMC6639751.

59. Russo S, Anker CJ, Wahab MA, Azad N, Bianchi N, Das P, Dragovic J, Goodman KA, Jones W 3rd, Kennedy T, Kumar R, Lee P, Sharma N, Small W, Suh WW, **Jabbour SK**.Executive Summary of the ARS Appropriate Use Criteria for Treatment of Anal Cancer. Int J Radiat Oncol Biol Phys. 2019 Jul 6. pii: S0360-3016(19)33444-3.doi: 10.1016/j.ijrobp.2019.06.2544. [Epub ahead of print] Review. PubMed PMID: 31288054.

60. Sayan M, Yegya-Raman N, Greco SH, Gui B, Zhang A, Chundury A, Grandhi MS, Hochster HS, Kennedy TJ, Langan RC, Malhotra U, Rustgi VK, Shah MM, Spencer KR,Carpizo DR, Nosher JL, **Jabbour SK**. Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes. Front Oncol. 2019 Jun 18;9:345. doi: 10.3389/fonc.2019.00345. eCollection 2019. Review. PubMed PMID: 31275846; PubMed Central PMCID: PMC6591511.

61. Zhang A, Deek MP, Kim S, Sayan M, Grann A, Wagman RT, Malhotra U, Hathout L, Biswal N, Zhang Y, Langenfeld J, Kennedy T, August DA, **Jabbour SK**. Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity. J Gastrointest Oncol. 2019 Jun;10(3):513-522. doi: 10.21037/jgo.2019.01.20. PubMed PMID: 31183202

62. Osorio B, Yegya-Raman N, Kim S, Simone CB 2nd, Theodorou Ross C, Deek MP,Gaines D, Zou W, Lin L, Malhotra J, Nie K, Aisner J, **Jabbour SK**. Clinical significance of pretreatment tumor growth rate for locally advanced non-small cell lung cancer. Ann Transl Med. 2019 Mar;7(5):95. doi: 10.21037/atm.2019.02.14. PubMed PMID: 31019945; PubMed Central PMCID: PMC6462644.

63. Sebastian N, Wu T, Bazan J, Driscoll E, Willers H, Yegya-Raman N, Bond L,Dwivedi A, Mo X, Tan Y, Xu-Welliver M, Haglund K, **Jabbour SK**, Keane FK, Williams TM. Pre-treatment neutrophil-lymphocyte ratio is associated with overall mortality in localized non-small cell lung cancer treated with stereotactic body radiotherapy. Radiother Oncol. 2019 May;134:151-157. doi: 10.1016/j.radonc.2019.01.032. Epub 2019 Feb 15. PubMed PMID: 31005209.

64. Ali ND, Donohue K, Zandieh S, Chen C, Moore D, Poplin E, Shah MM, Nosher J, Gui B, **Jabbour SK**, Spencer K, Carpizo DR. Conditional Survival Analysis of Metastatic Colorectal Cancer Patients Living ≥24 Months: A Single Institutional Study. Am J Clin Oncol. 2019 Apr 9. doi: 10.1097/COC.0000000000000535. [Epub ahead of print] PubMed PMID: 30973370.

65. Gupta A, Khan AJ, Goyal S, Millevoi R, Elsebai N, **Jabbour SK**, Yue NJ, Haffty BG, Parikh RR. Insurance Approval for Proton Beam Therapy and its Impact on Delays in Treatment. Int J Radiat Oncol Biol Phys. 2018 Dec 14. pii:S0360-3016(18)34187-7. doi: 10.1016/j.ijrobp.2018.12.021. [Epub ahead of print] PubMed PMID: 30557673.

66. Li D, Yegya-Raman N, Kim S, Ganesan S, Sayan M, August D, Spencer K, Hathout L, Maloney-Patel N, Malhotra U, Yue NJ, **Jabbour SK**. Multiple primary malignancies in patients with anal squamous cell carcinoma. J Gastrointest Oncol. 2018 Oct;9(5):853-857. doi: 10.21037/jgo.2018.06.07. PubMed PMID: 30505585; PubMed Central PMCID: PMC6219985.

67. Malhotra J, Rotter D, **Jabbour SK**, Aisner J, Lin Y, Manne S, Demissie K. Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer. Lung Cancer. 2018 Nov;125:205-211. doi: 10.1016/j.lungcan.2018.09.025. Epub 2018 Oct 1. PubMed PMID: 30429021.

68. Yegya-Raman N, Jhawar SR, **Jabbour SK**, Hussain S, Kim S. Radiation Therapy for Tracheobronchial Metastases from Head and Neck Squamous Cell Carcinoma. Cureus. 2018 Aug 15;10(8):e3151. doi: 10.7759/cureus.3151. PubMed PMID: 30345207; PubMed Central PMCID: PMC6191010.

69. Meleis A, Jhawar SR, Weiner JP, Majmundar N, Mahtabfar A, Lin Y, **Jabbour S,** Danish S, Goyal S. Stereotactic Body Radiation Therapy in Non-Surgical Patients with Metastatic Spinal Disease and Epidural Compression:A Retrospective Review. World Neurosurg. 2018 Oct 8. pii: S1878-8750(18)32265-4. doi:10.1016/j.wneu.2018.09.210. [Epub ahead of print] PubMed PMID: 30308345.

70. David JM, Gresham G, **Jabbour SK**, Deek M, Thomassian S, Robertson JM, Newman NB, Herman JM, Osipov A, Kabolizadeh P, Tuli R. Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer. J Gastrointest Oncol. 2018

Aug;9(4):641-649. doi: 10.21037/jgo.2018.03.10. PubMed PMID: 30151260; PubMed Central PMCID: PMC6087868.

71. Yegya-Raman N, Reyhan M, Kim S, Deek MP, Yue N, Zou W, Malhotra J, Aisner J, **Jabbour SK**. Association of Target Volume Margins With Locoregional Control and Acute Toxicities for Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy. Pract Radiat Oncol. 2018 Aug 23. pii:S1879-8500(18)30253-4. doi: 10.1016/j.prro.2018.08.007. [Epub ahead of print]PubMed PMID: 30144583.

72. Zou W, Burgdorf B, Yue NJ, Yin L, Zhang M, Khan A, **Jabbour SK**, McDonough J, Dong L, Teo BK. Efficient double-scattering proton therapy with a patient-specific bolus. Phys Med. 2018 Jun;50:1-6. doi: 10.1016/j.ejmp.2018.05.003. Epub 2018 May 26. PubMed PMID: 29891088.

73. Yegya-Raman N, Wang K, Kim S, Reyhan M, Deek MP, Sayan M, Li D, Patel M, Malhotra J, Aisner J, Marks LB, **Jabbour SK**. Dosimetric Predictors of Symptomatic Cardiac Events after Conventional-Dose Chemoradiation Therapy for Inoperable Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30675-0. doi: 10.1016/j.jtho.2018.05.028. [Epub ahead of print] PubMed PMID: 29883836.

74. Hathout L, Maloney-Patel N, Malhotra U, Wang SJ, Chokhavatia S, Dalal I,Poplin E, **Jabbour SK**. Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. J Gastrointest Oncol. 2018 Apr;9(2):363-376. doi:10.21037/jgo.2017.10.10. Review. PubMed PMID: 29755777; PubMed Central PMCID: PMC5934158.

75. Weiner AA, Gui B, Newman NB, Nosher JL, Yousseff F, Lu SE, Foltz GM, Carpizo D, Lowenthal J, Zuckerman DA, Benson B, Olsen JR, **Jabbour SK**, Parikh PJ. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases. J Vasc Interv Radiol. 2018 May 10. pii: S1051-0443(18)30960-6. doi: 10.1016/j.jvir.2018.02.020. [Epub ahead of print] PubMed PMID: 29754852.

76. Deek MP, Kim S, Beck R, Yegya-Raman N, Langenfeld J, Malhotra J, Mahmoud O, Aisner J, **Jabbour SK**. Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non-Small Cell Lung Cancer Are Associated With Decreases in Overall Survival. Clin Lung Cancer. 2018 Jul;19(4):e381-e390. doi: 10.1016/j.cllc.2018.03.007. Epub 2018 Mar 17. PubMed PMID: 29752011.

77. Yegya-Raman N, Kim S, Deek MP, Li D, Gupta A, Bond L, Dwivedi A, Braver JK, Reyhan M, Mittal A, Gui B, Malhotra J, Aisner J, **Jabbour SK**. Daily Image Guidance
With Cone Beam Computed Tomography May Reduce Radiation Pneumonitis in Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1104-1112. doi: 10.1016/j.ijrobp.2018.03.025. Epub 2018 Mar 30. PubMed PMID: 29730063.

78. Huang Q, **Jabbour SK**, Xiao Z, Yue N, Wang X, Cao H, Kuang Y, Zhang Y, Nie K. Dosimetric feasibility of 4DCT-ventilation imaging guided proton therapy for locally advanced non-small-cell lung cancer. Radiat Oncol. 2018 Apr 25;13(1):78. doi: 10.1186/s13014-018-1018-x. PubMed PMID: 29695284; PubMed Central PMCID: PMC5918906.

79. Chen T, Zhang M, **Jabbour S**, Wang H, Barbee D, Das IJ, Yue N. Principal component analysis-based imaging angle determination for 3D motion monitoring

using single-slice on-board imaging. Med Phys. 2018 Jun;45(6):2377-2387. doi: 10.1002/mp.12904. Epub 2018 Apr 25. PubMed PMID: 29635762.

80. Newman JH, Augeri DJ, NeMoyer R, Malhotra J, Langenfeld E, Chesson CB, Dobias NS, Lee MJ, Tarabichi S, Jhawar SR, Bommareddy PK, Marshall S, Sadimin ET, Kerrigan JE, Goedken M, Minerowicz C, **Jabbour SK**, Li S, Carayannopolous MO, Zloza A, Langenfeld J. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. Oncogene. 2018 Jul;37(27):3672-3685. doi: 10.1038/s41388-018-0156-9. Epub 2018 Apr 6. PubMed PMID: 29622797.

81. Wang SJ, Hathout L, Malhotra U, Maloney-Patel N, Kilic S, Poplin E, **Jabbour SK**. Decision-Making Strategy for Rectal Cancer Management Using Radiation Therapy for Elderly or Comorbid Patients. Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):926-944. doi: 10.1016/j.ijrobp.2017.12.261. Review. PubMed PMID: 29485072.

82. Xiao Z, Zou WJ, Chen T, Yue NJ, **Jabbour SK**, Parikh R, Zhang M. Using gEUD based plan analysis method to evaluate proton vs. photon plans for lung cancer radiation therapy. J Appl Clin Med Phys. 2018 Mar;19(2):204-210. PMID: 29436163.

83. Zheng S, **Jabbour SK**, O'Reilly SE, Lu JJ, Dong L, Ding L, Xiao Y, Yue N, Wang F, Zou W. Automated Information Extraction on Treatment and Prognosis for Non-Small Cell Lung Cancer Radiotherapy Patients: Clinical Study. JMIR Med Inform. 2018 Feb 1;6(1):e8. doi: 10.2196/medinform.8662. PubMed PMID: 29391345.

84. Herman JM, **Jabbour SK**, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, Narang AK, Pawlik TM, Hruban RH, Wolfgang CL, Iacobuzio-Donahue CA. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas. 2018 Feb;47(2):208-212. PMID: 23129157.

85. Sozio SJ, **Jabbour S**, Parikh R, Kim S. Locoregional Failure Rounds: A Meaningful Quality Improvement Project. J Am Coll Radiol. 2017 Dec 6. pii: S1546-1440(17)31284-X. doi: 10.1016/j.jacr.2017.10.005. [Epub ahead of print] No abstract available. J Am Coll Radiol. 2017 Dec 6. pii: S1546-1440(17)31284-X. doi: 10.1016/j.jacr.2017.10.005. [Epub ahead of print] No abstract available. PMID: 29221998.

86. Apisarnthanarax S, **Jabbour SK**, Liauw SL, Murphy JD, Olsen JR, Chang DT. Gastrointestinal Cancers: Timing Is Everything. Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1051-1058. doi: 10.1016/j.ijrobp.2017.05.040. No abstract available. PMID: 29165271.

87. Ma R, Levy M, Gui B, Lu SE, Narra V, Goyal S, Danish S, Hanft S, Khan AJ, Malhotra J, Motwani S, **Jabbour SK**. Risk of leptomeningeal carcinomatosis in patients with brain metastases treated with stereotactic radiosurgery. J Neurooncol. 2017 Nov 20. doi: 10.1007/s11060-017-2666-7. [Epub ahead of print] PMID: 29159778.

88. Malhotra J, **Jabbour SK**, Aisner J. Erratum to current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017 Oct;6(5):612. doi: 10.21037/tlcr.2017.08.08. PMID: 29114477.

89. Cercek A, Gendel V, **Jabbour S**, Moore D, Chen C, Nosher J, Capanu M, Chou JF, Boucher T, Kemeny N, Carpizo DR. A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with

Chemo-refractory Hepatic Colorectal Metastases. Curr Treat Options Oncol. 2017 Jul;18(7):42. doi: 10.1007/s11864-017-0481-1. Review. PubMed PMID: 28608276.

90. Hadzitheodorou C, Moss RA, Kennedy TJ, **Jabbour SK**. Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series. Case Rep Oncol. 2017 Apr 4;10(1):308-315. doi: 10.1159/000464280. eCollection 2017 Jan-Apr. PubMed PMID: 28512415; PubMed Central PMCID: PMC5422732.

91. Green WR, Chokshi R, **Jabbour SK**, DeLaney TF, Mahmoud O. Utilization pattern and survival outcomes of adjuvant therapies in high-grade nonretroperitoneal abdominal soft tissue sarcoma: A population-based study. Asia Pac J Clin Oncol.2017 May 2. doi: 10.1111/ajco.12683. [Epub ahead of print] PubMed PMID: 28464497.

92. Gui B, Weiner AA, Nosher J, Lu SE, Foltz GM, Hasan O, Kim SK, Gendel V, Mani NB, Carpizo DR, Saad NE, Kennedy TJ, Zuckerman DA, Olsen JR, Parikh PJ, **Jabbour SK**. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. Am J Clin Oncol. 2017 Apr 17. doi: 10.1097/COC.0000000000000384. [Epub ahead of print] PubMed PMID: 28418940.

93. Verma V, Shostrom VK, Zhen W, Zhang M, Braunstein SE, Holland J, Hallemeier CL, Harkenrider MM, Iskhanian A, **Jabbour SK**, Attia A, Lee P, Wang K, Decker RH, McGarry RC, Simone CB 2nd. Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis. Int J Radiat OncolBiol Phys. 2017 Mar 15;97(4):778-785. PubMed PMID: 28244414.

94. Jones WE 3rd, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J,Goodman KA, **Jabbour SK**, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Small W Jr, Herman JM; Expert Panel on Radiation OncologyGastrointestinal.. ACR Appropriateness Criteria® Resectable Pancreatic Cancer. Am J Clin Oncol. 2017 Apr;40(2):109-117.. PubMed PMID: 28230650.

95. Verma V, Simone CB 2nd, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM,Hallemeier CL, **Jabbour SK**, Matthiesen CL, Braunstein SE, Lee P, Dilling TJ, Allen BG, Nichols EM, Attia A, Zeng J, Biswas T, Paximadis P, Wang F, Walker JM, Stahl JM, Daly ME, Decker RH, Hales RK, Willers H, Videtic GM, Mehta MP, Lin SH. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):362-371. PubMed PMID: 28011047.

96. Verma V, Shostrom VK, Kumar SS, Zhen W, Hallemeier CL, Braunstein SE, Holland J, Harkenrider MM, S Iskhanian A, Neboori HJ, **Jabbour SK**, Attia A, Lee P, Alite F, Walker JM, Stahl JM, Wang K, Bingham BS, Hadzitheodorou C, Decker RH, McGarry RC, Simone CB 2nd. Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors. Cancer. 2017 Feb 15;123(4):688-696.. PubMed PMID: 27741355.

97. Deek, MP; Kim S; Yue N, Baby R, Ahmed I, Zou W, Langenfeld JP, Aisner J, **Jabbour SK**. Modern radiotherapy using image guidance for unresectable non-small cell lung cancer can improve outcomes in patients treated with chemoradiation therapy, Journal of Thoracic Disease, in press

98. Yao KJ, **Jabbour S**, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health

Statistics Database. BMC Gastroenterology, DOI: 10.1186/s12876-016-0527, in press

99. Ahmed I, Ferro A, Baby R, Malhotra J, Cohler A, Langenfeld J, Aisner J, Zou W, **Jabbour SK**. Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival. J Cancer Res Ther. 2016 Apr-Jun;12(2):952-8. doi: 10.4103/0973-1482.177214. PubMed PMID: 27461680.

100. Deek MP, Kim S, Ahmed I, Fang BS, Zou W, Malhotra J, Aisner J, **Jabbour SK**. Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Am J Clin Oncol. 2016 Jun 17. [Epub ahead of print] PubMed PMID: 27322697.

101. Small W Jr, Hayes JP, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Goodman KA, **Jabbour SK**, Jones WE 3rd, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Herman JM, ACR Appropriateness Criteria®Borderline and Unresectable Pancreas Cancer. Oncology (Williston Park). 2016 Jul 15;30(7).

102. Nie K, Shi L, Chen Q, Hu X, **Jabbour S**, Yue N, Niu T, Sun X. Rectal Cancer: Assessment of Neoadjuvant Chemo-Radiation Outcome Based on Radiomics of Multi-Parametric MRI. Clin Cancer Res. 2016 May 16. pii: clincanres.2997.2015 PMID: 27185368

103. Chang JY, **Jabbour SK**, De Ruysscher D, Schild SE, Simone CB 2nd, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS; International Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee. Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):505-16. doi: 10.1016/j.ijrobp.2016.01.036. PMID: 27084663

104. Deek MP, Nagarajan S, Kim S, Ahmed I, Paul S, Scher ED, Listo M, Chen A, Aisner J, Hussain S, Haffty BG, **Jabbour SK**. Clinical Characteristics and Dose Volume Histogram Parameters Associated With Pleural Effusion in Non-Small Cell Lung Cancer Patients Treated With Chemoradiation Therapy. Acta Oncologica, 18 May 2016, :1-6

105. Chuong MD, Hallemeier CL, **Jabbour SK**, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):488-97. doi: 10.1016/j.ijrobp.2015.11.043. PMID: 27084662

106. Rasheed A, **Jabbour SK**, Rosenberg S, Patel A, Goyal S, Haffty BG, Yue NJ, Khan A. Motion and volumetric change as demonstrated by 4DCT: The effects of abdominal compression on the GTV, lungs, and heart in lung cancer patients. Pract Radiat Oncol. 2015 Dec 19. pii: S1879-8500(15)00454-3. doi: 10.1016/j.prro.2015.12.006 PMID: 26922698

107. Emerson LY, Deek MP, Almendral J, **Jabbour SK**. Radiation therapy in patients with left ventricular assist device: A Case report and literature review. Pract Radiat Oncol. 2015 Dec 7. pii: S1879-8500(15)00445-2. doi: 10.1016/j.prro.2015.12.003 PMID: 27017262.

108. Newman NB, Sidhu MK, Baby R, Moss RA, Nissenblatt MJ, Chen T, Lu SE, **Jabbour SK.** Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.

Int J Radiat Oncol Biol Phys. 2016 Apr 1; 94(5):1052-60. doi: 10.1016/j.ijrobp.2015.12.374. Epub 2016 Jan 5. PMID: 27026312.

109. Patel AA, Nagarajan S, Scher ED, Schonewolf CA, Balasubramanian S, Poplin E, Moss R, August D, Carpizo D, Melstrom L, **Jabbour SK**. Early vs. Late Chemoradiation Therapy and the Postoperative Interval to Adjuvant Therapy Do Not Correspond to Local Recurrence in Resected Pancreatic Cancer. Pancreat Disord Ther. 2015 Jun;5(2). pii: 151. Epub 2015 Apr 2 PMID: 26779392.

110. Diab N, Clark G, Langer L, Wang Y, Hamlington B, Brzeskiewicz L, O'Shaughnessy J, Diab S, **Jabbour SK.** Impact of race and tumor subtype on second malignancy risk in women with breast cancer. Springerplus. 2016 Jan 6; 5:14. doi: 10.1186/s40064-015-1657-4. eCollection 2016. PMID: 26759753.

111. Deek MP, Benenati B, Kim S, Chen T, Ahmed I, Zou W, Aisner J, **Jabbour SK**. Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):147-54. doi: 10.1016/j.ijrobp.2015.09.022. Epub 2015 Sep 25. PMID: 26700708.

112. Scher ED, Kim S, Deek MP, Ahmed I, Kothadia JP, Balasubramanian S, Aisner J, Goyal S, **Jabbour SK**. Ambulatory pulse oximetry as a clinical aid for the diagnosis and treatment response of radiation pneumonitis. Pract Radiat Oncol. 2015 Nov-Dec;5(6):e635-41. Epub 2015 Aug 20. PMID: 26547829.

113. Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, Goodman KA, Hong TS, **Jabbour SK**, Jones WE 3rd, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria® Local Excision in Early Stage Rectal Cancer. Am J Clin Oncol. 2015 Oct;38(5):520-5 PMID 26371522.

114. Daroui P, **Jabbour SK**, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Hong TS, Jones WE 3rd, Kaur H, Konski AA, Koong AC, Kumar R, Pawlik TM, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria® Resectable Stomach Cancer. Oncology (Williston Park). 2015 Aug;29(8):595-602, C3 PMID: 26281845.

115. Hong TS, Moughan J, Garofalo MC, Bendell J, Berger AC, Oldenburg NB, Anne PR, Perera F, Lee RJ, **Jabbour SK**, Nowlan A, DeNittis A, Crane C. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):29-36. Epub 2015 May 14. PMID: 26163334.

116. Newman NB, **Jabbour SK**, Hon JD, Berman JJ, Malik D, Carpizo D, Moss RA. Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review. J Clin Exp Hepatol. 2015 Jun;5(2):163-6. PMID: 261455045.

117. Wu AJ, Bosch WR, Chang DT, Hong TS, **Jabbour SK**, Kleinberg LR, Mamon HJ, Thomas CR Jr, Goodman KA. Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer. Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):911-20. PMID: 26104943.

118. **Jabbour SK**, Kim S, Haider SA, Xu X, Wu A, Surakanti S, Aisner J, Langenfeld J, Yue NJ, Haffty BG, Zou W. Reduction in Tumor Volume by Cone Beam Computed

Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):627-33. PMID: 26068495.

119. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti SG, Aisner J, Zou W, Haffty BG, **Jabbour SK**. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis. 2015 Mar;7(3):346-55. PMID: 25922712.

120. Zou W, Yin L, Shen J, Corradetti MN, Kirk M, Munbodh R, Fang P, **Jabbour SK**, Simone CB 2nd, Yue NJ, Rengan R, Teo BK. Dynamic simulation of motion effects in IMAT lung SBRT. Radiat Oncol. 2014 Nov 1;9:225 PMID 25365935

121. Goodman KA, Milgrom SA, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Hong TS, **Jabbour SK**, Jones WE 3rd, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW. ACR Appropriateness Criteria Rectal Cancer: Metastatic Disease at Presentation. Oncology. 2014 Oct 15; 28(10).

122. Chen T, Qin S, Xu X, **Jabbour SK**, Haffty BG, Yue NJ. Frequency Filtering based Analysis on the Cardiac Induced Lung Tumor Motion and Its Impact on the Radiotherapy Management. Radiotherapy and Oncology. September 2014 112(3):365-370 PMID: 25236714

123. Cruz JE, Saksena R, **Jabbour SK**, Nosher JL, Hermes-DeSantis E, Moss RA. The power of genes: a case of unusually severe systemic toxicity after localized hepatic chemoembolization with irinotecan-eluted microspheres for metastatic colon cancer. Annals of Pharmacotherapy. 26 December 2014, 48(12)1646-1650 5p. PMID 25202035

124. Ahmed I, Zou W, **Jabbour SK**. High does radiotherapy to automated implantable cardioverter-defibrillator: a case report and review of the literature. Case Rep Oncol Med. 2014, p1-4. 4p.

125. Schonewolf, C; Patel, B; Gensure, R; Narra, V; Haffty, BG; Nosher, J; **Jabbour, SK**; Patterns of Failure in Colorectal Patients with Liver Metastases after Yttrium-90 Radioembolization, American Journal of Clinical Oncology. 2014 Jun; 37(3):234-40.

126. **Jabbour SK**, Hashem S, Bosch W, Kim TKK, et al. Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. Practical Radiation Oncology 2014 Mar-Apr;4(2):82-9.

127. Schonewolf CA, Mehta M, Schiff D, Wu H, Haffty BG, Karantza V, **Jabbour SK.** Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation. World J Gastrointest Oncol. 2014 Mar 15;6(3):74-82.

128. Carpizo DR, Gensure RH, Yu X, Gendel VM, Greene SJ, Moore DF, **Jabbour SK,** Nosher JL. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. J Vasc Interv Radiol. 2014 Feb;25(2):297-306.

129. Expert Panel on Radiation Oncology–Rectal/Anal Cancer, Hong TS, Pretz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, **Jabbour SK**, Jones WE 3rd, Konski AA, Koong AC Rodriguez-Bigas M(5), Small W J), Thomas CR Jr, Zook J, Suh WW. ACR Appropriateness Criteria®-Anal Cancer.. Gastrointest Cancer Res. 2014 Jan;7(1):4-14.

130. Call JA, Prendergast BM, Jensen LG, Ord CB, Goodman KA, Jacob R, Mell LK,Thomas CR Jr, **Jabbour SK**, Miller RC. Intensity-modulated Radiation Therapy for Anal Cancer: Results from a Multi-Institutional Retrospective Cohort Study. Am J Clin Oncol. 2016 Feb; Vol. 39 (1), pp. 8-1. PMID: 24401669.

131. Ferro A, **Jabbour SK**, Taunk NK, Aisner J, Cohler A, Somalya S, Goyal S. Cranial irradiation in adults diagnosed with acute myelogenous leukemia presenting with hyperleukocytosis and neurologic dysfunction. Leuk Lymphoma; Jan 2014; 55; 1; p105-p109.

132. Chen T, **Jabbour SK**, Qin S, Haffty BG, Yue N. Objected constrained registration and manifold learning: a new patient setup approach in image guided radiation therapy of thoracic cancer. Med Phys. 2013 Apr;40(4).

133. Zhang M, Qin S, Chen T, Kim S, **Jabbour S**, Haffty B, Yue NJ. A clinical objective IMRT QA method based on portal dosimetry and electronic portal imager device (EPID) measurement. Technol Cancer Res Treat. 2013 Apr;12(2):145-50.

134. Tunceroglu A, Park JH, Balasubramanian S, Poppe M, Anker CJ, Poplin E, Moss RA, Yue NJ, Carpizo D, Gannon CJ, Haffty BG, **Jabbour SK**. Dose-painted intensity modulated radiation therapy improves local control for locally advanced pancreas cancer. ISRN Oncol. 2012;2012:572342. doi: 10.5402/2012/572342. Epub 2012 Oct 18. PubMed PMID: 23119186.

135. Jones WE 3rd, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, **Jabbour SK**, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW. ACR appropriateness criteria® resectable rectal cancer. Radiat Oncol. 2012 Sep 24;7:161. doi: 10.1186/1748-717X-7-161. PubMed PMID: 23006527.

136. **Jabbour SK**, Patel S, Herman JM, Wild A, Nagda SN, Altoos T, Tunceroglu A, Azad N, Gearheart S, Moss RA, Poplin E, Levinson LL, Chandra RA, Moore DF, Chen C, Haffty BG, Tuli R. Intensity-modulated radiation therapy for rectal carcinoma can reduce treatment breaks and emergency department visits. Int J Surg Oncol. 2012;2012:891067. doi: 10.1155/2012/891067. Epub 2012 Aug 13. PubMed PMID: 22934164.

137. Gensure RH, Foran DJ, Lee VM, Gendel VM, **Jabbour SK**, Carpizo DR, Nosher JL,Yang L. Evaluation of hepatic tumor response to yttrium-90 radioembolization therapy using texture signatures generated from contrast-enhanced CT images. Acad Radiol. 2012 Oct;19(10):1201-7. doi: 10.1016/j.acra.2012.04.015. Epub 2012 Jul 26. PubMed PMID: 22841288.

138. Kothadia JP, Chhabra S, Marcus A, May M, Saraiya B, **Jabbour SK**. Anterior mediastinal mass in a young marijuana smoker: a rare case of small-cell lung cancer. Case Rep Med. 2012;2012:754231. doi: 10.1155/2012/754231. Epub 2012 Apr 1. PubMed PMID: 22545056.

139. **Jabbour SK**, Daroui P, Moore D, Licitra E, Gabel M, Aisner J. A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis. 2011 Mar;3(1):4-9. doi: 10.3978/j.issn.2072-1439.2010.12.09. PubMed PMID: 22263057.

140. Nosher, JL; Ohman-Strickland, PA; **Jabbour S**; Narra V; Nosher B; Changes in Liver and Spleen Volumes and Liver Function after Radioembolization with Yttrium-90 Resin Microspheres; J Vasc Interv Radiology, 2011 Dec; 22(12): 1706 – 13.

141. Poppe, M.M.; Narra, V. ; Nelson, C.; **Jabbour, SK**; Comparison of Helical Intensity Modulated Radiotherapy (H-IMRT), IMRT and 3D Conformal Radiation Therapy (3DCRT) for Pancreatic Cancer Medical Dosimetry; Medical Dosimetry, 2010.

142. Zhou J; Kim S; **Jabbour S**; Goyal S; Haffty B; Chen T; Levinson L; Metaxas D; Yue NJ; A 3D global-to-local deformable mesh model based registration and anatomy-constrained segmentation method for image guided prostate radiotherapy; Med Phys, MAR, 2010; 37; **3**; p1298-p1308.

143. Chen, T; Kim, S; Goyal, S; **Jabbour, S**; Rajagopal, G; Haffty, B; Yue, **N**; Object-constrained meshless deformable algorithm for high speed 3D nonrigid registration between CT and CBCT; Med Phys; Volume 37, No 1: pages 197-210, 2010.

144. Yovino S; Poppe M; **Jabbour S**; David V; Garofalo MC; Pandya N; Hanna N; Alexander R; Doyle A; Regine WF; Intensity-Modulated Radiation Therapy (IMRT) Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers: A Multi-Institutional Experience; International Journal of Radiation Oncology, Biology, Physics, Volume 79, Issue 1: Pages 158-162, January 2011.

145. **Jabbour, SK**; Zhang, Z; Arnold, D; Wharam, W.D; Risk of Second Tumor in Intracranial Germinoma Patients Treated with Radiation Therapy: The Johns Hopkins Experience; Journal of Neuro-Oncology, Volume 1, No 2: pages 227-232, 2008.

146. Yue, N. J; Kim, S; Lewis, B.E; **Jabbour, SK**; Narra, V; Goyal, S; Haffty, B.G; Optimization of couch translational corrections to compensate for rotational and deformable target deviations in image guided radiotherapy; Medical Physics, Volume 35, No 10: pages 4375-4385, 2008.

147. Yue, N. J; Kim, S; **Jabbour, SK**; Narra, V; Haffty, B.G; A strategy to objectively evaluate the necessity of correcting detected target deviations in image guided radiotherapy; Medical Physics, Volume 34, No 11: pages 4340-4347, 2007.

148. Raza, S.M; **Jabbour, SK**; Thai, Q; Pradilla, G; Kleinberg, L.R; Wharam, M; Rigamonti, D; Repeat stereotactic radiosurgery for high-grade and large intracranial arteriovenous malformations; Surgical Neurology, Volume 68, No 1: pages 24-34, 2007.

149. Chang, S; Zhou, J; Liu, Q; Metaxas, D.N; Haffty, B.G; Kim, S; **Jabbour, SK;** Yue, N.J; Registration of lung tissue between fluoroscope and CT images: determination of beam gating parameters in radiotherapy; Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv, Volume 10, No 1: pages 751-758, 2007.

150. Nwokedi, E.C; DiBiase, S.J; **Jabbour, SK**; Herman, J; Amin, P; Chin, L.S; Gamma Knife stereotactic radiosurgery for patients with glioblastoma multiforme; Neurosurgery, Volume 50, No 1: pages 41-46, 2002.

151. Bourdi, M; Demady, D; Martin, J.L; **Jabbour, SK**; Martin, B.M; George, J.W; Pohl, L.R; cDNA Cloning and baculovirus expression of the human liver endoplasmic reticulum P58: characterization as a protein disulfide isomerase isoform, but not as a Protease or a carnitine acyltransferase; Archives of Biochemistry and Biophysics, Volume 323, No 2: pages 397-403, 1995.

B. Books, Monographs and Chapters

1. Jabbour SK, Yom SS. Building a Disease Group; Academic Radiation Oncology, Ed: Thomas, Vepiwala, 2021

2. Gupta A, Wang SJ, Jabbour SK; Stagina and Initial Evaluation. Anal Cancer, Kachnic and Meyer, Spring 2019

3. Byun J, **Jabbour, SK**; Haffty B; Goyal S; Radioembolization; In: Precision Oncology, 2017

4. Ahlawat, A; Baby, R; **Jabbour S.K.** Upper GI Normal Anatomy in Hong and Das Editors, GI Radiotherapy, 2016

5. Editor for GI sections in Radiation Oncology in A Question Based Review, by Hristov, Lin and Christodouleas, 2014

6. **Jabbour, S.K.**; Small, W.; Anal IMRT; In: Difficult Cases in Radiation Oncology, 2011

7. Lin,S.; **Jabbour, S.K.**; Hristov, B., Christodouleas, J.; Gastric Cancer; In: Radiation Oncology Review, 2010

8. Hristov, B.; **Jabbour, S.K.**; Lin,S., Christodouleas, J.; Anal Cancer; In: Radiation Oncology Review, 2010

9. Susil R, **Jabbour S.K.**; Lin, S., Hristov,B., Christodouleas, J.; Biliary Cancer; In: Radiation Oncology Review, 2010

10. Christodouleas, J.; **Jabbour, S.K.**; Lin, L., Hristov, B.; Hepatic Cancer; In: Radiation Oncology Review, 2010

11. Herman, J.; **Jabbour, S.K.**; Ettinger, D.; Radiosensitizers in Oncology; In: Current Cancer Therapeutics, 2009

12. **Jabbour, S.K.;** Frassica, D.; Haffty, B.G., Wilson,L.; Anal Cancer; In: Handbook of Radiation Oncology, 2008

13. Goyal,Sharad; **Jabbour, S.K.;** Haffty, B.G.; Wilson,L.; Gastric Cancer; In: Handbook of Radiation Oncology, 2008

14. Song, D; **Jabbour, S.K.;** DeWeese, T.L.; Kirby, R.S.; Partin,A.W.; Feneley, M.R.; Parsons, R; Radiotherapy for the Treatment of Locally Advanced and Metastatic Prostate Cancer; In: Prostate Cancer: Principles and Practice; 2006

C. Patents Held N/A

D. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications

152. Workman SW, Deek M**, Jabbour S**. A Narrative Review of Genetic Biomarkers in Non-Small Cell Lung Cancer: An Update and Future Perspectives. Chinese Journal of Thoracic Surgery. 2022 May 12.

153. Khullar K, Patrich T, **Jabbour SK**, Hathout L. Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose. Appl Radiat Oncol. 2022 Mar;11(1):14-20. PMID: 35445143; PMCID: PMC9017798.

154. Yom SS, Deville C Jr, Boerma M, Carlson D, **Jabbour SK**, Braverman L. Evaluating the Generalizability and Reproducibility of Scientific Research. Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):1-4. doi: 10.1016/j.ijrobp.2022.02.002. PMID: 35427541.

155. Khullar K, Patrich T, **Jabbour SK**, Hathout L. Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose. Appl Radiat Oncol. 2022 Mar;11(1):14-20. PMID: 35445143; PMCID: PMC9017798.

156. **Jabbour SK**, Keller SM, Reck M. Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply. JAMA Oncol. 2021 Nov 4. doi: 10.1001/jamaoncol.2021.5611. Epub ahead of print. PMID: 34734971.

157. Jhawar SR, Palmer JD, Wang SJ, Bitterman D, Klamer B, Huynh-Le M, Chung C, Ohri N, Stover DG, Lustberg MB, Mishra S, Warner J, **Jabbour S**, Goyal S; CCC19 Radiation Oncology Group. The COVID-19 & Cancer Consortium (CCC19) and Opportunities for Radiation Oncology. Adv Radiat Oncol. 2021 Jan-Feb;6(1):100614. doi: 10.1016/j.adro.2020.10.026. Epub 2020 Dec 24. PMID: 33521393; PMCID: PMC7834122.

158. Modi C, Berim L, Isserow L, Malhotra J, Patel M, Langenfeld J, Aisner J, Almeldin D, **Jabbour SK**. Combining radiation therapy and immunotherapy for lung cancers: a narrative review. Shanghai Chest. 2021 Jan;5:10. doi: 10.21037/shc-20-66. Epub 2021 Jan 10. PMID: 33521559; PMCID: PMC7842553.

159. Hallemeier CL, Huguet F, Tait D, Buckstein MH, Anker CJ, Kharofa J, Olsen JR, **Jabbour SK**. Randomized Trials for Esophageal, Liver, Pancreas, and Rectal Cancers. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):305-311. doi: 10.1016/j.ijrobp.2020.09.033. PMID: 33422270.

160. Almeldin DS, Malhotra J, Patel M, Aisner J, **Jabbour SK**. Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)-current consensus and future perspectives. J Thorac Dis. 2020 Nov;12(11):7069-7075. doi: 10.21037/jtd-20-1485. PMID: 33282413; PMCID: PMC7711375.

161. Sayan M, Mamidanna S, Fuat Eren M, Daliparty V, Zoto Mustafayev T, Nelson C, Ohri N, **Jabbour SK**, Guven Mert A, Atalar B. New horizons from novel therapies in malignant pleural mesothelioma. Adv Respir Med. 2020;88(4):343-351. doi: 10.5603/ARM.a2020.0103. PMID: 32869268.

162. Khullar K, Patel NM, Anderson C, Chundury A, Carpizo D, Feingold D, Grandhi M, Hochster H, Jani K, Kennedy T, Langan R, Spencer K, August D, **Jabbour SK**. The Evolving Role of Radiotherapy in Locally Advanced Rectal Cancer and the Potential for Nonoperative Management. Oncol Hematol Rev. 2020 Spring;16(1):43-51. Epub 2020 Apr 27. PMID: 32832093; PMCID: PMC7439775.

163. **Jabbour S**, Simone CB 2nd, Malhotra J. Assessing Expression of PD-L1 in Tumor-Associated Macrophages-Reply. JAMA Oncol. 2020 Aug 6. doi: 10.1001/jamaoncol.2020.2722. Epub ahead of print. PMID: 32761104.

164. Neibart SS, Manne SL, **Jabbour SK**. Quality of Life After Radiotherapy for Rectal and Anal Cancer. Curr Colorectal Cancer Rep. 2020 Feb;16(1):1-10. doi:

10.1007/s11888-019-00448-w. Epub 2020 Jan 16. PMID: 32632345; PMCID: PMC7336840.

165. Simone CB 2nd, Plastaras JP, **Jabbour SK**, Lee A, Lee NY, Choi JI, Frank SJ, Chang JY, Bradley J. Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. Semin Radiat Oncol. 2020 Jul;30(3):253-261. doi: 10.1016/j.semradonc.2020.02.007. PMID: 32503791.

166. Kharofa J, Hallemeier CL, Huguet F, Anker CJ, Buckstein MH, Tait D, Olsen JR, **Jabbour SK**. Gastrointestinal Cancers: Moving the Needle for Rectal, Gastroesophageal, Pancreaticobiliary, and Liver Cancers. Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):653-662. doi: 10.1016/j.ijrobp.2019.12.011. PMID: 32092335.

167. Sayan M, Eren MF, Gupta A, Ohri N, Kotek A, Babalioglu I, Oskeroglu Kaplan S, Duran O, Derinalp Or O, Cukurcayir F, Kurtul N, Ceylaner Bicakci B, Kutuk T, Senyurek S, Turk A, **Jabbour SK**, Atalar B. Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm. Adv Respir Med. 2019;87(5):289-297. doi: 10.5603/ARM.2019.0051. PMID: 31680229.

168. Olsen JR, Apisarnthanarax S, Murphy JD, Tait D, Huguet F, Hallemeier CL,**Jabbour SK**. Gastrointestinal Cancers: Fine-Tuning the Management of Rectal,Esophageal, and Pancreas Cancers. Int J Radiat Oncol Biol Phys. 2019 Sep 1;105(1):1-10. doi: 10.1016/j.ijrobp.2019.04.037. Review. PubMed PMID: 31422802

169. Hallemeier CL, Olsen JR, Murphy JD, Tait D, Apisarnthanarax S, Huguet F**, Jabbour SK**. Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers. Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):1-9. doi: 10.1016/j.ijrobp.2018.12.052. PubMed PMID: 30967220.

170. **Jabbour SK**, Timmerman RD, Raben D, DeWeese TL, Donaldson SS, Thomas P, Laurie F, Bishop-Jodoin M, Tarbell N, Wolden S, Halperin E, Constine LS, Haas-Kogan D, Marcus K, Freeman C, Terezakis S, Million L, Smith MA, Mendenhall NP, Marcus RB Jr, Cherlow J, Kalapurakal J, Breneman J, Yock T, MacDonald S, Laack N, Donahue B, Indelicato D, Michalski J, Perkins S, Kachnic L, Esiashvilli N, Roberts KB,FitzGerald TJ. Moody D. Wharam Jr, MD, FACR, FASTRO, July 22, 1941-August 10,2018. Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1026-1030. doi:10.1016/j.ijrobp.2019.01.004. Epub 2019 Mar 13. PubMed PMID: 30900552.

171. Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, **Jabbour SK**. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer. 2018 Aug;1. pii: 20.doi: 10.21037/apc.2018.07.05. Epub 2018 Aug 6. PubMedPMID: 30687847; PubMed Central PMCID: PMC6345263

172. Amin NP, Mohindra P, **Jabbour SK**. Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer. J Thorac Dis. 2018 Nov;10(Suppl33):S4108-S4112. doi: 10.21037/jtd.2018.09.143. PubMed PMID: 30631568; PubMed Central PMCID: PMC6297498.

173. Patel M, Malhotra J, **Jabbour SK**. Examining EML4-ALK variants in the clinical setting: the next frontier? J Thorac Dis. 2018 Nov;10(Suppl 33):S4104-S4107. doi: 10.21037/jtd.2018.11.07. PubMed PMID: 30631567; PubMed Central PMCID: PMC6297451

174. Berman AT, **Jabbour SK**, Vachani A, Robinson C, Choi JI, Mohindra P, Rengan R,

Bradley J, Simone CB 2nd. Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res. 2019 Feb;8(1):5-14. doi: 10.21037/tlcr.2018.12.12. Review. PubMed PMID: 30788230; PubMed Central PMCID: PMC6351405.

175. Yegya-Raman N, Shah MM, Grandhi MS, Poplin E, August DA, Kennedy TJ, Malhotra U, Spencer KR, Carpizo DR, **Jabbour SK**. Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma. Ann Pancreat Cancer. 2018 Aug;1. pii: 20.doi: 10.21037/apc.2018.07.05. Epub 2018 Aug 6. PubMed PMID: 30687847; PubMed Central PMCID: PMC6345263.

176. Amin NP, Mohindra P, **Jabbour SK**. Serum microRNA guiding personalized radiation therapy in non-small cell lung cancer. J Thorac Dis. 2018 Nov;10(Suppl 33):S4108-S4112. doi: 10.21037/jtd.2018.09.143. PubMed PMID: 30631568; PubMed Central PMCID: PMC6297498.

177. Patel M, Malhotra J, **Jabbour SK**. Examining EML4-ALK variants in the clinical setting: the next frontier? J Thorac Dis. 2018 Nov;10(Suppl 33):S4104-S4107. doi:10.21037/jtd.2018.11.07. PubMed PMID: 30631567; PubMed Central PMCID: PMC6297451.

178. Yegya-Raman N, Zou W, Nie K, Malhotra J, **Jabbour SK**. Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy. J Thorac Dis. 2018 Aug;10(Suppl 21):S2474-S2491. doi: 10.21037/jtd.2018.07.29. Review. PubMed PMID: 30206493; PubMed Central PMCID: PMC6123184.

179. Olsen JR, Murphy JD, Huguet F, Hallemeier CL, Apisarnthanarax S, **Jabbour SK**. Gastrointestinal Cancers-Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):233-242. doi: 10.1016/j.ijrobp.2018.05.026. PubMed PMID: 30191854.

180. Patel M, **Jabbour SK,** Malhotra J. ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water? J Thorac Dis. 2018 Jul;10(Suppl 18):S2198-S2201. doi: 10.21037/jtd.2018.06.118. PubMed PMID: 30123560; PubMed Central PMCID: PMC6072958.

181. **Jabbour SK**, Apisarnthanarax S, Hallemeier CL,Huguet F, Murphy JD, Olsen JR. GI Cancers-Modulating the Modern Management of Gastrointestinal Malignancies: A Look at Liver Metastases, Rectal Cancer,Esophagogastric Cancer, and Anal Cancer. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):749-758. doi:10.1016/j.ijrobp.2017.11.031. Epub 2018 Jun 20. PubMed PMID: 29976479.

182. Olsen JR, Murphy JD, Hallemeier CL, Apisarnthanarax S, Huguet F, **Jabbour SK**. Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database. J Clin Oncol. 2018 Aug 20;36(24):2564-2565. doi:10.1200/JCO.2018.78.2904. Epub 2018 Jun 26. PubMed PMID: 29945521.

183. **Jabbour SK**, Apisarnthanarax S, Hallemeier CL, Huguet F, Murphy JD, Olsen JR. GI Cancers-Modulating the Modern Management of Gastrointestinal Malignancies: A Look at Liver Metastases, Rectal Cancer, Esophagogastric Cancer, and Anal Cancer. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):749-758. doi: 10.1016/j.ijrobp.2017.11.031. Epub 2018 Jun 20. PubMed PMID: 29976479.

184. Olsen JR, Murphy JD, Hallemeier CL, Apisarnthanarax S, Huguet F, **Jabbour SK**. Cross-Modality Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy for Treatment of Hepatocellular Carcinoma: Limitations of the National Cancer Database. J Clin Oncol. 2018 Jun 26:JCO2018782904. doi:10.1200/JCO.2018.78.2904. [Epub ahead of print] PubMed PMID: 29945521.

185. Malhotra J, **Jabbour SK**. Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer. Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S138-S141. doi: 10.21037/tlcr.2018.03.09.PubMed PMID: 29782572; PubMed Central PMCID: PMC5943224.

186. **Jabbour SK**, Berman AT, Simone CB 2nd. Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 2017 Apr;6(2):113-118. doi:10.21037/tlcr.2017.04.02. Review. PubMed PMID: 28529894.

187. Hathout L, Williams TM, **Jabbour SK**. The Impact of Novel Radiation Treatment Techniques on Toxicity and Clinical Outcomes In Rectal Cancer. Curr Colorectal Cancer Rep. 2017 Feb;13(1):61-72. doi: 10.1007/s11888-017-0351-z. Epub 2017 Mar 10. PubMed PMID: 29445322.

188. Simone CB 2nd, Berman AT, **Jabbour SK**. Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies. Transl Lung Cancer Res. 2017 Apr;6(2):109-112. doi: 10.21037/tlcr.2017.04.05. PubMed PMID: 28529893; PubMed Central PMCID: PMC5420536.

189. Malhotra J, **Jabbour SK**, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res. 2017 Apr;6(2):196-211. doi: 10.21037/tlcr.2017.03.01. Review. PubMed PMID: 28529902; PubMed Central PMCID: PMC5420529.

190. Jamorabo DS, Lin SH, **Jabbour SK**. Successes and failures of combined modalities in upper gastrointestinal malignancies: new direction. Seminars in Radiation Oncology, 2016 (invited review)

191. Apisarnthanarax S, Chia-Hsien Cheng J, **Jabbour SK**, Liauw SL, Murphy JD, Chang DT. Gastrointestinal Cancers-Changing the Standard for Rectal Cancer and Establishing a New Standard for Liver Tumors. Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):930-6. doi: 10.1016/j.ijrobp.2016.02.024. PubMed PMID: 27302509 (invited editorial)

192. Patel AN, Simone CB 2nd, **Jabbour SK.** Risk factors and management of oligometastatic non-small cell lung cancer. Ther Adv Respir Dis. 2016 Apr 8. pii: 1753465816642636 PMID: 2760187 (invited review)

193. Chang DT, **Jabbour SK**, Brunner T, Cheng JC, Liauw SL, Meyer J, Wo J. Key New Studies in Gastric and Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):475-81 PMID: 26460987. (invited editorial)

194. Nosher JL, Ahmed I, Patel AN, Gendel V, Murillo PG, Moss R, **Jabbour SK**. Non-operative therapies for colorectal liver metastases. J Gastrointest Oncol. 2015 Apr;6(2):224-40 PMID: 25830041 (invited review)

195. **Jabbour SK**. Are We Expanding Oligometastatic Non-Small-Cell Lung Cancer Using Advanced Radiotherapeutic Modalities? J Clin Oncol. 2014 Oct 27. PMID: 25349298 (invited editorial)

196. Scher ED, Ahmed I, Yue NJ, **Jabbour SK.** Technical aspects of radiation therapy for anal cancer. J Gastrointest Oncol. 2014 Jun;5(3):198-211. (invited review)

197. Kumar RJ, **Jabbour SK**. Neodjuvant therapy for resectable and borderline resectable pancreatic cancer. J Radiat Oncol (2013) 2: 353. doi:10.1007/s13566-013-0120-9. (invited review)

198. Tian S, Hirshfield KM, **Jabbour SK**, Toppmeyer D, Haffty BG, Khan AJ, Goyal S.Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol, 2014 Oct 9; 4:277. (review)

199. **Jabbour SK**, Mulvihill D. Defining the role of adjuvant therapy: ampullary and duodenal adenocarcinoma. Semin Radiat Oncol. 2014 Apr;24(2):85-93.(invited review)

200. Tunceroglu, A; **Jabbour, SK**; Gastric Cancer – Past Accomplishments, Present Approaches, and Future Aspriations; Clinical Practice, January 2013, 10(1):47-77. (invited review)

201. **Jabbour, SK**; Thomas, C.R.; Radiation Therapy in the Postoperative Management of Esophageal Cancer; Journal of Gastrointestinal Oncology, Dec;Volume 1(2), pp.102-11 No 2: 2010. (invited review)

E. Selected Abstracts

1. C. Hadzitheodorou, S. Kim, W. Zou, **S.K. Jabbour**. Relationship Between Treatment Outcomes and Tumor Volume Reduction Evaluated by Cone-Beam Computed Tomography during Stereotactic Body Radiotherapy. ASTRO 2016, Boston, MA

2. R. Beck; M.P. Deek, S.K. Jabbour, Radiation Dose Effect in Adjuvant Chemoradiation for Locally Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinomas, ASTRO 2016, Boston, MA

3. B.Gui, A.A. Weiner, J. Nosher, S.Lu, G.M. Foltz, O. Hasan, S.K. Kim, V. Gendel, N.B. Mani, MD, D. Carpizo, N.E. Saad,T. Kennedy, D.A. Zuckerman, J.R. Olsen, P.J. Parikh, S.K.Jabbour. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated with Radioembolization. ASTRO 2016, Boston, MA

4. N.B. Newman, P.A. Ohman-Strickland, D. Carpizo, B. Benson, R.H. Gensure, C.A. Schonewolf, R.A. Moss, L. Melstrom, J.L. Nosher, **S.K. Jabbour**. Predictors of Survival in Yttrium-90 Radioembolization of Hepatic Malignancies With Resin Microspheres. International Journal of Radiation Oncology, Biology, Physics. Nov2015 Supplement, Vol. 93 Issue 3, pE132-E133, ASTRO 2015, San Antonio, TX

5. M.P. Deek, I. Ahmed, S. Kim, B. Fang, J.W. Zou, J. Aisner, B.G. Haffty, **S.K. Jabbour**. Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Unresectable Non-Small Cell Lung Cancer Patients. Proceedings of the American Society for Radiation Oncology 57th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 1 November 2015 93(3) Supplement:E413, ASTRO 2015, San Antonio, TX

6. N.B. Newman, M.K. Sidhu, R. Baby, R.A. Moss, C. Rezac, E. Poplin, N.M. Patel, **S.K. Jabbour.** Association Between Neoadjuvant Chemoradiation Therapy and

Hematologic Toxicity During Adjuvant Chemotherapy in Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. Nov2015 Supplement, Vol. 93 Issue 3, pE168-E168, ASTRO 2015, San Antonio, TX.

7. N.B. Newman, M.K. Sidhu, R. Baby, R.A. Moss, E. Poplin, N.M. Patel, C. Rezac, S. Goyal, M.D. Becker, **S.K. Jabbour**. Dosimetric Parameters That Are Associated With Acute Hematologic Toxicity and FDG-PET/CT Changes in Anal Cancer Patients After Chemoradiation. International Journal of Radiation Oncology, Biology, Physics. Nov2015 Supplement, Vol. 93 Issue 3, pE160-E160, ASTRO 2015, San Antonio, TX

8. **S.K. Jabbour**, C.M. Descaris, M.P. Deek, L. Lin, S. Kim, W. Zou, C.B. Simone II Cone Beam Computed Tomography Can Predict Survival of Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiation Therapy. Proceedings of the American Society for Radiation Oncology 57th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 1 November 2015 93(3) Supplement:S162 , ASTRO 2015, San Antonio, TX

9. **S.K. Jabbour**, M.P. Deek, P. Daroui, S. Balasubramanian, D. Moore, M. Moran, S. Astrow, B.G. Haffty, J. Aisner. Overexpression of Excision Repair Cross Complementing-1 Gene May Predict Local Recurrence After Definitive Chemoradiation for Unresectable Non-Small Cell Lung Cancer. Proceedings of the American Society for Radiation Oncology 57th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 1 November 2015 93(3) Supplement:S160., ASTRO 2015, San Antonio, TX

10. W. Zou, N.J. Yue, L. Yin, M. Zhang, A.J. Khan, **S.K. Jabbour**, B.G. Haffty, J. McDonough, B.K.K. Teo.. Efficient Double-Scattered Proton Treatment Delivery With a Patient Specific Bolus. Proceedings of the American Society for Radiation Oncology 57th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics 1 November 2015 93(3) Supplement:S165-S166., ASTRO 2015, San Antonio, TX

11. S. Zheng, F. Wang, H. Gan, J. Lu, **S. Jabbour**, N. Yue, W. Zou. Patient Treatment and Prognosis Information Extraction With Adaptive Self Learning Medical Form Generating System. International Journal of Radiation Oncology, Biology Physics; SEP 1, 2014; 90; pS819-pS819, ASTRO 2014, San Francisco, CA

12. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti S, Aisner J, Zou W, Haffty BG, **Jabbour S.K.** Impact of metformin use on survival in non-small cell lung cancer treated with definitive radiation therapy. In Proceedings of the American Society for Radiation Oncology 56th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 1 September 2014 90(1) Supplement:S633-S634, ASTRO 2014, San Francisco, CA

13. T.S. Hong, J. Moughan, M. Garofalo, J. Bendell, A.C. Berger, N.B. Oldenburg, P.A. Anne, F. Perera, R.J. Lee, **S.K. Jabbour**, A. Nowlan, A.S. DeNittis, C.H. Crane. Efficacy Outcomes from RTOG 0822: A Phase II Study of Neoadjuvant IMRT with Capecitabine (c) and Oxaliplatin (o) in Patients with Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics SEP 1, 2014; 90; pS21-pS21, ASTRO 2014, San Francisco, CA

14. Ahmed I, Ferro A, Aisner J, Surakanti S, Haider SA, Langenfeld J, Cohler A, Zou W, **Jabbour S.K**. Survival benefit with carboplatin-based induction chemotherapy for bulky Stage II & III inoperable non-small cell lung cancer. International Journal of Radiation Oncology Biology Physics; SEP 1, 2014; 90; pS634-pS634, ASTRO

2014, San Francisco, CA

15. J. Wu, K. A. Goodman, D. T. Chang, T. S. Hong, **S.K. Jabbour**, L. R. Kleinberg, H. J. Mamon, C. R. Thomas, W. R. Bosch. Generation of Consensus Contour Atlas for Esophageal Cancer IMRT, ASTRO, Atlanta, Georgia 2013. Proceedings of the American Society for Radiation Oncology 55th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 1 October 2013 87(2), ASTRO 2013, Atlanta, GA

16. Patel, A., C. Schonewolf, S. Balasubramanian, R. Moss, L. Melstrom, B. G. Haffty, **Jabbour, S.K.** Postoperative Interval between Surgery and Initiation of Adjuvant Therapy Corresponds to Local Recurrence in Resected Pancreatic Cancer, Atlanta Georgia International Journal of Radiation Oncology Biology Physics; 2013. OCT 1, 2013; 87; 2; pS313-pS313, ASTRO 2013, Atlanta, GA

17. Rasheed, **S.K. Jabbour**, S. Rosenberg, A. Patel, S. Goyal, B. G. Haffty, N. J. Yue, A. Khan. The Effects of Abdominal Compression on the Motion and Volume of the GTV, Lungs & Heart in Lung Cancer Patients; ASTRO 2013, Atlanta, GA

18. S. A. Haider, W. Zou, X. Xu, S. Balasubramanian, A. Wu, N. J. Yue, B. G. Haffty, **Jabbour**, **S.K.** Correlation of Survival to CBCT-based Tumor Response during Chemoradiation in Patients with Stage III Non-Small-Cell Lung Cancer; ASTRO, Atlanta, Georgia 2013. International Journal of Radiation Oncology Biology Physics OCT 1, 2013; 87; 2; pS540-pS541, ASTRO 2013, Atlanta, GA.

19. Kothadia, JP; Kim, S; Balasubramanian, S; Walker, J; Haffty, BG; **Jabbour, SK;** Walking Pulse Oximetry as a Clinical Aid in the Diagnosis of Radiation Pneumonitis; ASTRO 2012, Boston, Massachusetts

20. Schonewolf, C; Patel, B; Gensure, R; Narra, V; Haffty, BG; Nosher, J; **Jabbour, SK**; Patterns of Failure in Colorectal Patients with Liver Metastases after Yttrium-90 Radioembolization, ASTRO Proc IEEE Int Symp Biomed Imaging, 2012 Boston Massachusetts

21. Chen, T; Qin, S; **Jabbour, SK;** Park, J; Haffty, BG; Yue, NJ; A Quantitative Study Of The Correlations of Lung Tumor Motion to Cardiac and Respiratory Motion; ASTRO 2012, Boston, MA

22. Qin, S; Zhu, X; Chen, T; **Jabbour, SK;** Zhang, M; Haffty, BG; Yue, N; Motion Pattern for Liver Tumor and Its Correlation to External Surrogates; ASTRO 2012, Boston, MA

23. Rosenberg, S; **Jabbour, SK;** Yue, NJ; Rasheed, A; Haffty, BG; Goyal, S; Khan, A; Variability of Tumor Motion in 4DCT: the Effects of Abdominal Compression on Lung Tumor Displacement; ASTRO 2012, Boston, MA

24. Schonewolf, CA; Mehta, M; Schiff, D; Wu, H; Haffty, BG; Karantza, V; **Jabbour, SK;** Autophagy Inhibition by Chloroquine Sensitizes Colorectal Cancer Cells to Concurrent Chemoradiation; ASTRO 2012, Boston, MA

25. Tanceroglu, A; Park, J; Poppe, M; Balasubramanian, S; Hernandez, D; Poplin, E; Carpizo, D; Gannon, C; Haffty, BG; **Jabbour, SK;** Dose-painted Intensity Modulated Radiation Therapy May Offer Improved Morbidity as Compared to 3D-CRT; ASTRO 2012, Boston, Massachusetts

26. Park, J; Qin, S; Chen, T; **Jabbour, SK;** Haffty, BG; Yue, NJ; A 4D adaptive approach to improve pre-treatment positioning accuracy in lung cancer radiation treatments; ASTRO 2012, Boston, MA

27. Hong T, et al. A Phase II Evaluation of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) in Combination with Capecitabine and Oxaliplatin for Patients with Locally Advanced Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics. 2011 81(2) Supplement :S3-S4, ASTRO 2011, Miami, FL

28. **Jabbour, SK;** Tuli, R; Patel, S; Chandra, R; Chen, C; Moore, D; Herman, J; Intensity Modulated Radiation Therapy (IMRT) for Rectal Cancer Can Reduce Acute Toxicities of Chemoradiation; International Journal of Radiation Oncology, Biology, Physics, Volume 78, Issue 3: Page S324, ATSTRO 2010, San Diego, CA.

29. **Jabbour, SK.;** Poster: Rectal Intensity Modulated Radiation Therapy Appears to Reduce Acute Toxicities of Treatment; American Radium Society 2010, Cancun, Mexico.

30. Liu B; Yang L; Kulikowski C; Zhou J; Gong L; Foran DJ; **Jabbour, SK**; Yue NJ; An Adaptive Tracking Algorithm of Lung Tumors in Fluoroscopy using online learned collaborative trackers; Proc IEEE Int Symp Biomed Imaging, 2010, Rotterdam, Netherlands.

31. Zhou, J; Goyal, S; Kim, S; Khan, A; **Jabbour, SK**, Rao, M; Haffty, B; Yue, N.J.; A Free Form Deformation-based 3D Registration Algorithm for Image Guided Breast Radiotherapy; International Journal of Radiation Oncology, Biology,Physics, Volume 75, Issue 3: Pages S713-S714, ASTRO 2009, Chicago, IL

32. **C**hen, T; Kim,S; Zhou, J; Rajagopal, G; Goyal, S; **Jabbour, SK**; Haffty, B; Yue, N.J.; Fast 3-D Non-rigid CT and CBCT Registration in Head & Neck IGRT; International Journal of Radiation Oncology, Biology, Physics, Volume 75, Issue 3: Pages S625-S626, November 2009, Chicago, IL

33. M.M. Poppe, V. Narra, **S.K. Jabbour**. Is TomoTherapy Superior to Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiation Therapy (3D-CRT) in the Treatment of Pancreatic Cancer? Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 2008 72(1) Supplement :S283-S284, ASTRO 2008, Boston , MA

34. S.G. Yovino, M.C. Garofalo, V. David, M. Poppe, **S. Jabbour**, N. Hanna, R. Alexander, N. Pandya, W.F. Regine IMRT Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers: A Multi-institutional Experience. Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Annual Meeting, International Journal of Radiation Oncology, Biology, Physics. 2008 72(1) Supplement :S254 , ASTRO 2008, Boston , MA

35. **Jabbour, SK;** Daroui,P; Gabel, M; Sovak, M; Cohler, A; Aisner, J; A Novel Paradigm in the Treatment of Oligometastatic Non-Small Cell Lung Cancer; International Journal of Radiation Oncology, Biology, Physics, Volume 72, Issue 1: Page S469, September 2008, ASTRO 2008, Boston , MA

36. J.P. Christodouleas, D.B. Yeater, **Jabbour, SK**; L. Mangold, E.S. Leman, R. Drew, E. Humphreys, A.W. Partin, R.H. Getzenberg, T.L. DeWeese Modulation of EPCA-2 Levels in Men with Localized Prostate Cancer Treated with Radiation with or

without Androgen Suppression Therapy. International Journal of Radiation Oncology Biology Physics; 2008; 72; 1; pS316-pS316, ASTRO 2008, Boston, MA

37. **Jabbour, SK.;** Poster: Is intensity modulated radiation therapy (IMRT) superior in the treatment of pancreatic cancer? A dosimetric comparison of IMRT and 3D conformal radiation therapy (3D-CRT); ASCO- Gastrointestinal Cancers Symposium, 2008; Abstract # 236., San Francisco, CA

38. **Jabbour, SK;** Abstract: Gamma Knife Radiosurgery for Treatment of Brain Metastases: How is Whole Brain Radiation Dose Affected by Improved Conformality?; Society for Neuro-Oncology; OCT, 2006; 8; 4; p486-p487, Orlando, FL, 2006.

39. **Jabbour, SK.;** Poster: Clinical Experience as Part of the Palliative Medicine Team at the University of Pittsburgh; American College of Radiation Oncology 2005, Las Vegas, NV

F. Reports N/A

PRESENTATIONS (Selected):

A. Scientific

1. **S.K. Jabbour;** B. Houghton; A.G. Robinson; X. Quantin; T. Wehler; D. Kowalski; M.-J. Ahn; M. Erman; G. Giaccone; H. Borghaei; J. McLean; Y. Xu; F. Souza; G. Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non–small cell lung cancer (NSCLC): KEYNOTE-867. Trial in Progress, ASCO 2022, June 6, 2022, Chicago, IL

2. **Salma K. Jabbour**; Ki Hyeong Lee, MD; Nikolaj Frost; Valeriy Breder; Dariusz M. Kowalski; Issam Alawin; Evgeny Levchenko; Noemi Reguart; Alex Martinez-Martí; Baerin Houghton; Jean-Baptiste Paoli; Sufia Safina; Keunchil Park; Takefumi Komiya; Amy Sanford; Vishal Boolell; Hong Liu; Ayman Samkari; Steven M. Keller; Martin Reck, KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC, ASTRO 2021 Lung Oral Presentation, October 24, 2021, Chicago, IL

3. **Salma K. Jabbour,** Ki Hyeong Lee, Nicolaj Frost, Dariusz Kowalski, Valeriy Vladimirovich Breder, Theodore Pollock, Noemi Reguart, Baerin Houghton, Xavier Quantin, Steven M. Keller, Hong Liu, Bilal Piperdi, Martin Reck; Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. ASCO 2021

4. Reck, M. Lee KH, Frost N, Kowalski DM, et al (**Jabbour, Senior Author**). Pembrolizumab plus platinum chemotherapy and radiotherapy in unresectable, locally advanced, stage III NSCLC: KEYNOTE-799. Presented at the the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer (WCLC) Singapore; January 28-31, 2021; Virtual. Abstract OA02.03

5. **Salma K. Jabbour,** Baerin Houghton, Andrew G. Robinson, Xavier Quantin, Thomas Wehler, Dariusz Kowalski, Myung-Ju Ahn, Mustafa Erman, Giuseppe Giaccone, Hossein Borghaei, Jessica McLean, Jin Zhang, Fabricio Souza, Roy Decker, Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body

Radiotherapy With or Without Pembrolizumab in Patients With Inoperable Stage I/IIA Non–Small-Cell Lung Cancer: KEYNOTE-867, ASTRO 2020

6. **Salma K. Jabbour,** Ki Hyeong Lee, Nicolaj Frost, Dariusz Kowalski, Valeriy Vladimirovich Breder, Theodore Pollock, Noemi Reguart, Baerin Houghton, Xavier Quantin, Steven M. Keller, Hong Liu, Bilal Piperdi, Martin Reck; Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799. Abstract 9008, ASCO 2020

7. **Salma K. Jabbour,** Baerin Houghton, Andrew G. Robinson, Xavier Quantin, Thomas Wehler, Dariusz Kowalski, Myung-Ju Ahn, Mustafa Erman, Giuseppe Giaccone, Hossein Borghaei, Jessica McLean, Jin Zhang, Fabricio Souza, Roy Decker, Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy With or Without Pembrolizumab in Patients With Inoperable Stage I/IIA Non–Small-Cell Lung Cancer: KEYNOTE-867, AACR 2020

8. **Jabbour SK**, Park K, Cohn D, Liu H, Keller S, Kowalski DM, Phase 2 Trial of First-Line Pembrolizumab With Platinum Doublet Chemotherapy and Radiotherapy in Patients With Unresectable, Locally Advanced Stage III Non–Small-Cell Lung Cancer: KEYNOTE-799, Poster, Chicago, IL, June 2, 2019

9. **Jabbour SK**, Berman AT, Decker R, Zloza A, Feigenberg S, Gettinger S, Aggarwal C, Langer C, Simone C, Bradley J, Lin Y, Aisner J, Malhotra J. PD-1 Blockade with pembrolizumab during concurrent chemoradiation for locally advanced non-small cell lung cancer, ASCO Poster Discussion, Chicago, IL, June 2, 2019,

10. **Jabbour SK**, Berman AT, Decker R, Zloza A, Feigenberg S, Gettinger S, Aggarwal C, Langer C, Simone C, Bradley J, Lin Y, Aisner J, Malhotra J. PD-1 Blockade with pembrolizumab during concurrent chemoradiation for locally advanced non-small cell lung cancer, Society of Immunotherapy for Cancer, Washington, D.C., November 2018

11. **Jabbour, SK**; Oral Poster Session: Cone Beam Computed Tomography Can Predict Survival of Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Chemoradiation Therapy. American Society for Radiation Oncology, San Antonio, TX, October 2015

12. **Jabbour, SK**; Oral Poster Session: Overexpression of Excision Repair Cross Complementing-1 Gene May Predict Local Recurrence After Definitive Chemoradiation for Unresectable Non-Small Cell Lung Cancer. American Society for Radiation Oncology, San Antonio, TX, October 2015

13. **Jabbour, SK**; Oral Abstract Presentation: Overexpression of Excision Repair Cross Complementing-1 Gene May Predict Local Recurrence After Definitive Chemoradiation for Unresectable Non-Small Cell Lung Cancer. American Radium Society, St. Thomas, May 2014

14. Modulation of Autophagy with Chloroquine, 5-FU and Radiation in Colorectal Cancer, CINJ Clinical Investigators Program, New Brunswick, NJ April 13, 2012

15. **Jabbour, SK.;** Oral Plenary Session Presentation: Risk of Second Tumors in Intracranial Germinoma Patients Treated with Radiation Therapy; Second International Symposium on CNS Germ Cell Tumors, Los Angeles, California, 2005.

16. **Jabbour, SK.;** Oral Presentation: Repeated Stereotactic Radiosurgery Can Result in Complete Obliteration for Large Intracranial Arteriovenous Malformations; ASTRO, Denver, Colorado, 2005.

B. Professional (Clinical):

1. University of Pennsylvania Grand Rounds Speaker, The Landscape of Immunotherapy and Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer, Philadelphia, PA, October 5, 2022

2. University of Pennsylvania Radiation Oncology Lecture, Controversies and Future Directions in Rectal Cancer, Philadelphia, PA, October 5, 2022

3. OncLive Educational Summit, Chemo-immunotherapy Combinations in Early-Stage Lung Cancer, New Brunswick, NJ, September 20, 2022

4. Yale Visiting Professorship & Grand Rounds, Department of Radiation Oncology, Combining Immunotherapy and Radiation Therapy in Stage III NSCLC, New Haven, CT, April 21, 2022

5. Columbia University Grand Rounds, Department of Radiation Oncology, Combining Immunotherapy and Radiation Therapy in Stage III NSCLC, Virtual, April 8, 2022

6. Medscape Liver Virtual Conference for Perspectives in Lung Cancer Care, The Role of Radiation Therapy in Small Cell Lung Cancer, March 18, 2022

7. Society of Surgical Oncology Virtual Tumor Board, Management of Gastric Cancers, February 21, 2022

8. The New York Lung Cancer Foundation Meeting, Stage III Unresectable NSCLC-the Radiation Oncology Perspective, Virtual Meeting, January 20, 2222

9. Society of Surgical Oncology Virtual Tumor Board, Neoadjuvant/Adjuvant Immunotherapy for Esophageal & Gastric Cancers, December 6, 2021

10. 2021 Multidisciplinary Thoracic Cancers Symposium, Combining Immunotherapy and Radiation Therapy, Scottsdale, AZ, December 3, 2021

11. 2021 Multidisciplinary Thoracic Cancers Symposium, Chronic Issues from Systemic Therapy, Scottsdale, AZ, December 3, 2021

12. 2021 Multidisciplinary Thoracic Cancers Symposium, How to Get Your Paper Published, Scottsdale, AZ, December 3, 2021

13. Virtual Lung Cancer Awareness Virtual Event, Rutgers American Pharmacists Association, November 17, 2021

14. RBHS Research Summit, Controversies in Stereotactic Body Radiation Therapy, New Brunswick, NJ, November 13, 2021

15. ASTRO Annual Meeting, Practical Radiation Oncology: Updates in Esophageal and Rectal Cancers, Chicago, IL, October 23, 2021

16. International Society of Gastrointestinal Oncology, Early Stage Colorectal Cancer: Radiation Therapy First, October 2, 2201, Miami, FL/Virtual Session

17. International Association for the Study of Lung Cancer (IASLC), How to Create Your First Clinical Trial, September 13, 2021, Virtual Session

18. Global Collaborative Oncology Group, The University of Hong Kong-HKU Shenzhen Hospital. A Training Program for Radiation Technology and Combined Radiation and Immune Therapy, RTOG OAR Delineation, July 27, 2021; Liver Cancer Panelist, July 29, 2021, Virtual Session

19. INFORM: LUNGevity Patient Zoom Meeting: April 20, 2021, Virtual Session

20. Medical Crossfire: Radiation and Medical Oncology Assess Immuno-Oncology Strategies in Stage III NSCLC. February 24, 2021, Virtual Session at ACRO

21. ASTRO, Ask a Radiation Oncologist: Radiation Therapy for Lung Cancer, November 30, 2020

22. Radiation Therapy Planning for KEYLYNK-013 in Small Cell Lung Cancer, International Virtual Investigators Meeting, October 20, 2020

23. ASTRO Annual Virtual Meeting, Cardiac Effects of Radiotherapy, Moderator, October 25, 2020

24. ASTRO Annual Virtual Meeting, GI Practical Radiation Oncology, Case Discussion: Locally Advanced Rectal, Pancreatic and Esophageal Cancer, October 24, 2020

25. Very Rare Cancer Consortium Virtual Meeting, Anal Cancer and Second Malignancy, September 17, 2020

26. Overview of Radiation Therapy for Keylink-012 and Stage III Non-Small Cell Lung Cancer, International Virtual Investigators Meeting, May 12, 2020

27. The Current Landscape for Stage III Non-Small Cell Lung Cancer, NRG Oncology Translational Science Lung Cancer Session, Houston, TX, January 10, 2020

28. Anorectal Cancer: Patterns of Failure Guiding Treatment Planning; ASTRO Webinar, December 4, 2019

29. Shanghai 2nd International Lung Cancer Forum: Review of the Current Therapeutic and Research Landscape for Stage III Non-Small Cell Lung Cancer, Shanghai, China, October 27, 2019

30. Scientific Input Engagement, Merck: Updates in Immunotherapy for Stage III Lung Cancer, Chicago, IL, September 14, 2019

31. ASTRO Annual Meeting 2019, Science Highlights: Gastrointestinal, Chicago, IL September 16, 2019

32. ASTRO Annual Meeting 2019, eContouring in Gastrointestinal Cancers, Chicago, IL September 16, 2019

33. ASTRO Annual Meeting 2019, Practical Radiation Oncology, Case Discussion: Locally Advanced Rectal Cancer Chicago, IL, September 14, 2019

34. ASTRO Annual Meeting 2019, Clinical Trial Development: Lessons Learned, Chicago, IL, September 14, 2019

35. GI Symposium: Update on the Management of Gastrointestinal and Liver Disorders, HCC, Cholangiocarcinoma Management, Jersey City, NJ, April 27, 2019

36. ASCO GI, Innovations in Multimodality Management of Rectal Cancer--Radiotherapy for Rectal Cancer: Beyond the German Rectal Trial, San Francisco, CA, January 19, 2019

37. Mt. Sinai Department of Radiation Oncology Grand Rounds and Visiting Professor, New York, NY, November 30, 2018

38. ASTRO Thought Leaders in Lung Cancer, Radiation Therapy for Lung Cancer, Arlington, VA, November 7, 2018

39. ASTRO Annual Meeting 2018, eContouring in Gastrointestinal Cancers, San Antonio, TX, October 21, 2018

40. ASTRO Annual Meeting, 2018, Clinical Trials Development—Inside vs Outside a Cooperative Group, San Antonio, TX, October 24, 2018

41. ASTRO Annual Meeting, 2018, GI Posters, Walk with a Professor, San Antonio, TX, October 22, 2018

42. Big Ten Cancer Research Consortium (BTCRC) Summit, Radiation Oncology in the BTCRC, Chicago, IL, September 29, 2018,

43. Merck Investigators Meeting: Updated Staging in Non-Small Cell Lung Cancer, Immunotherapy combined with Chemoradiation for Stage III Non-Small Cell Lung Cancer, Hollywood, CA, September 13-14, 2018

44. NRG Oncology, Translational Science Lung Cancer Workshop, Checkpoint Inhibition in Chemoradiation for NSCLC, Philadelphia, PA, July 13, 2018

45. ACRO, Immunotherapy and Non-Small Cell Lung Cancer, February 2018, Orlando, FL

46. Imaging in Gastrointestinal Cancers in Radiation Oncology, RSNA, Chicago IL, November 27, 2017

47. Best of ASTRO, GI Abstract Review, Miami, FL, November 10, 2017

48. ASTRO, GI Science Highlights, Sand Diego, CA, September 27, 2017

49. Best of ASTRO, GI Abstract Review, Fort Lauderdale, FL, November 12, 2016

50. Mult-Institutional Clinical Trials Inside versus Outside of a Cooperative Group, Section Leader, Clinical Trials Design Course, University of Pennsylvania, October 19-20, 2016

51. Panelist on Combined Modality Therapy with Novel Radiosensitizers, Radiation Research Society, Waikoloa, HI, October 16, 2016

52. American Society of Radiation Oncology, Esophago-Gastric Cancer, Abstract Session Moderator, Boston, MA, September 28, 2016

53. Concepts to Advance Therapy for Non-Small Cell Lung Cancer University of Pennsylvania, Philadelphia, PA, August 24, 2016

54. American Radium Society, Stereotactic Body Radiotherapy Primer Course, Moderator, Philadelphia, PA, April 16, 2016

55. Best of ASTRO, GI Abstract Review, San Diego, CA, November 14, 2015

56. Combined Immunotherapy and Radiotherapy Rationale, Advances in Cancer Immunotherapy, Society for Immunotherapy in Cancer (SITC), Princeton University, Princeton, NJ, March 28, 2015

57. CBCT based response of Non-Small Cell Lung Cancer, Twitter.com, September 20, 2015

58. Practical Uses of Radiation Oncology in the Emergency Setting, Department of Family Medicine, New, Brunswick, NJ, UMDNJ, May 9, 2013

59. Uncertainties in Imaging for Radiation Oncology: Sources and Mitigation Techniques – Imaging Moving Targets, RSNA, Chicago, IL, November 25, 2012

60. Upper GI Session, American Society of Radiation Oncology (ASTRO) Poster Discussant, Boston, MA, October 30, 2012

61. Pancreas Cancer and Difficult Cases, International Society Gastrointestinal Oncology, Arlington, VA, September 13. 2012

62. Basics of Radiation Oncology, RWJMS Oncology Interest Group, Piscataway, NJ, March 12, 2012

63. Radiation Oncology for Non-Small Cell Lung Cancer, UMDNJ Division of Pulmonary Medicine Grand Rounds, New Brunswick, NJ, February 17, 2012

64. American Society of Radiation Oncology (ASTRO), Oral Abstract Upper GI Section Moderator, Miami, FL, October 4, 2011

65. Updates in Radiation Oncology for Non-Small Cell Lung Cancer, UMDNJ Thoracic Surgery Rounds, New Brunswick, NJ, November 10, 2010

66. Therapeutic Challenges in Pancreas Cancer, American Society of Radiation Oncology (ASTRO) Discussant, Pancreatic Cancer Oral Scientific Session, San Diego, CA, November 3, 2010

67. Clinical Trials Updates at CINJ and CINJOG, CINJOG Annual Retreat, Cancer Institute of New Jersey, New Brunswick, NJ, October 26, 2010

68. Updates in GI Radiation Oncology, Surgical Grand Rounds, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, September 29, 2010

69. Advances in Stereotactic Body Radiation Therapy for Lung Cancer, Somerset Hospital Grand Rounds, Somerset Hospital, Somerset, NJ, September 14, 2010

70. Locally Advanced Pancreatic Cancer: Advances in Treatment, CINJ, Hamilton, NJ, April 15, 2010

71. Targeted Therapies in Nuclear Medicine: MIBG and Peptide Receptor Radionuclide, RWJUH Neuroendocrine Tumor Board, New Brunswick, NJ, January 22, 2010

72. Best of Gastrointestinal Abstracts, Best of ASTRO 2009, University of Maryland School of Medicine, Refresher Course, Baltimore, MD, January 7, 2010

73. Integrated Science and Practice Keynote Speaker: Emerging Science and Controversies: Pancreas Cancer, Radiological Society of North America (RSNA), Chicago, Illinois, December 2, 2009

74. Selective Internal Radiation Therapy, Emerging Therapeutics Nursing Education: Advances in Surgical and Radiation Oncology, New Brunswick, NJ, November 19, 2009

75. Controversies and Challenges in Pancreatic Cancer, Raritan Bay Medical Center, Perth Amboy, NJ, May 26, 2009

76. Role of RT in Rectal Cancer, Associated Colon and Rectal Surgeons, Edison, NJ, August 26, 2008

77. Challenges in Thoracic Oncology, Johns Hopkins University, Baltimore, MD, December 6, 2007

78. Radiation Oncology 101, UMDNJ Lung Tumor Study Group, New Brunswick, NJ, August 23, 2007

79. Current Advances in Thoracic Radiation Oncology, Current Achievements in Thoracic Oncology Symposium, Jersey Shore Medical Center, Neptune, NJ, October 23, 2007

80. Imaging in Radiation Therapy, New Jersey Society of Radiologic Technologists, Robert Wood Johnson University Hospital, New Brunswick, NJ, September 30, 2006